CN1607945A - 有镶嵌部分的组合剂型 - Google Patents

有镶嵌部分的组合剂型 Download PDF

Info

Publication number
CN1607945A
CN1607945A CNA028234308A CN02823430A CN1607945A CN 1607945 A CN1607945 A CN 1607945A CN A028234308 A CNA028234308 A CN A028234308A CN 02823430 A CN02823430 A CN 02823430A CN 1607945 A CN1607945 A CN 1607945A
Authority
CN
China
Prior art keywords
dosage form
described dosage
shell
active component
molding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA028234308A
Other languages
English (en)
Other versions
CN100408029C (zh
Inventor
D·-Y·李
H·S·索登
M·托马斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/966,450 external-priority patent/US6982094B2/en
Priority claimed from US09/966,509 external-priority patent/US6767200B2/en
Priority claimed from US09/966,497 external-priority patent/US7122143B2/en
Priority claimed from US09/967,414 external-priority patent/US6742646B2/en
Priority claimed from US09/966,939 external-priority patent/US6837696B2/en
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Publication of CN1607945A publication Critical patent/CN1607945A/zh
Application granted granted Critical
Publication of CN100408029C publication Critical patent/CN100408029C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/02Apparatus specially adapted for manufacture or treatment of sweetmeats or confectionery; Accessories therefor
    • A23G3/04Sugar-cookers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G1/00Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/30Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/50Cocoa products, e.g. chocolate; Substitutes therefor characterised by shape, structure or physical form, e.g. products with an inedible support
    • A23G1/54Composite products, e.g. layered laminated, coated, filled
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/0002Processes of manufacture not relating to composition and compounding ingredients
    • A23G3/0004Processes specially adapted for manufacture or treatment of sweetmeats or confectionery
    • A23G3/0019Shaping of liquid, paste, powder; Manufacture of moulded articles, e.g. modelling, moulding, calendering
    • A23G3/0025Processes in which the material is shaped at least partially in a mould in the hollows of a surface, a drum, an endless band, or by a drop-by-drop casting or dispensing of the material on a surface, e.g. injection moulding, transfer moulding
    • A23G3/0029Moulding processes for hollow products, e.g. opened shell
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G3/368Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/50Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
    • A23G3/54Composite products, e.g. layered, coated, filled
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005Coating of tablets or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • A61K9/2826Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2873Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B30PRESSES
    • B30BPRESSES IN GENERAL
    • B30B11/00Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/02Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using a ram exerting pressure on the material in a moulding space
    • B30B11/08Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using a ram exerting pressure on the material in a moulding space co-operating with moulds carried by a turntable
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B30PRESSES
    • B30BPRESSES IN GENERAL
    • B30B11/00Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/34Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses for coating articles, e.g. tablets
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B30PRESSES
    • B30BPRESSES IN GENERAL
    • B30B15/00Details of, or accessories for, presses; Auxiliary measures in connection with pressing
    • B30B15/30Feeding material to presses
    • B30B15/302Feeding material in particulate or plastic state to moulding presses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2068Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/13Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/1352Polymer or resin containing [i.e., natural or synthetic]

Abstract

一种剂型包含至少一种活性成分,第一部分包含一个外表面和一个或多个腔,腔有至少一个带凹口的内表面和一个外表面,第二模塑部分镶嵌在第一部分的腔内和有一个外表面。第一和第二部分在界面上接触,第二部分包含凝固的热塑性物质,第二部分大体上正形地在第一部分的凹口上。在另一个实施方案中,剂型包含至少一种活性成分,片心有一个外表面,壳在片心外表面的至少一部分上存在,其特征在于,壳包含第一壳部分和镶嵌在第一壳部分的第二模塑壳部分。在另一个实施方案中,剂型包含至少一种活性成分,片心,和有不连续的第一模塑壳部分的壳,及连续的第二模塑壳部分,第一壳部分的不连续是由于第二模塑壳部分的存在,第一和第二壳部分在成分上是不同的。

Description

有镶嵌部分的组合剂型
发明背景
1.技术领域
本发明涉及组合剂型如药物组合物。更特别地,本发明涉及的组合剂型包含至少一种活性成分和第一部分及镶嵌在其中的模塑第二部分。
2.背景信息
包衣片剂,如薄膜包衣片剂、糖包衣片剂、胶囊片(gelcap)和凝胶片(geltab)被用作固体口服剂型,与无包衣片剂相比,在美观性、稳定性和易吞咽性上都有改进。特别有用的是,对固体剂型提供了独特的美观特性,以支持它们在市场上的识别与区分。薄膜包衣和糖包衣一般通过在旋转盘中喷雾获得,而它们可以各种颜色调配,通常只有一种颜色可用于围绕片心的全部,胶囊片和凝胶片可通过浸渍包衣、涂糖衣和胶囊壳收缩贴在片心的表面来制备。这些方法能使用多种颜色,但受到其它限制。
通过涂糖衣方法制备胶囊片和凝胶片的薄膜制剂,该方法如美国专利5,146,730和5,459,983所公开的内容,通常包含基于水的明胶制品,该制品包含占重量约45%明胶和约9%增塑剂(甘油和/或山梨糖醇)。据报道增塑剂在该制剂中起重要作用。增塑剂与明胶的比率低导致围绕片心的包衣易碎,而增塑剂与明胶的比率高导致围绕片剂的明胶包衣有柔性和可从片剂上剥落。如果需要附着产品片心的明胶包衣,则应考虑明胶制剂成分中占重量40%到60%明胶,5%到12%增塑剂,35%到50%水,和在0.1%到3%范围的着色剂和色素。甘油和山梨糖醇可以单独用作增塑剂或联合使用。另外,其他糖和多羟基化合物可用作添加剂和增塑剂。如果需要的终产品是防拆封的明胶包衣药物片剂,则明胶制剂中增塑剂与明胶的比率应在约1∶5的范围。该水平的增塑剂的要求对涂糖衣的剂型会带来限制,包括吸收水分的倾向,该倾向会危及产品的物理和化学稳定性,也增加制剂的成本。
现在另一种在片心(或基质)上形成壳(或包衣)的方法是WO 01/57144所公开的利用静电沉积的原理形成包衣的方法。这个方法的局限在于片心或壳中至少有一个必须掺合一种或多种“电荷控制剂”,如水杨酸金属盐,例如水杨酸锌、水杨酸镁、水杨酸钙;四价铵盐;苯扎氯铵;氯化苄乙氧铵;三甲基十四烷基溴化铵(溴化十六烷基三甲铵);和环糊精和它们的加合物;其量占壳的重量约1%到约10%。电荷控制剂常产生不舒服的味觉,另外会不利地增加在采用的电荷控制剂中的壳的氧化。
常规的包囊和涂糖衣加工的其它局限性在于其复杂性和高成本,壳或包衣厚度的限制,和在一半胶囊和/或包衣之间产生隆起的接缝。因此希望有本发明的剂型。这些剂型对许多应用增加了多用性,包括释放药物、营养剂和/或糖膏剂的剂型,其形式可以是凝胶片或胶囊片,包衣片剂,高效剂型等等。而且,这些剂型具有独特和舒适的美观特性,这在市场上是有价值的。
用压制(方法)产生片剂包衣是已知的,产生多堆叠层,或是片心或壳的外形。该包衣的形状与片心的形状大体上无关,如WO 00/18447所公开的内容。商品化的压制包衣设备可由例如Korsch美国公司(Korsch AG的一个子公司)提供,在WO89/11968中有描述。通过压制制备的改进释放剂型在美国专利5,738,874和6,294,200,和WO 99/51209中有例子。通过压制包衣来生产二部分的壳是可能的,该壳可以作为屏障或释放延迟包衣,但是压制包衣系统受到壳的厚度和壳的成分以及加工成本的限制。例如,Gunsel等的“压制包衣的片剂和层片剂”(Compression-coated and layer tablets),在H.A.Lieberman,L.Lachman,J.B.Schwartz编的《药物剂型一片剂》(Pharmaceutical Dosage Forms-Tablets)中(修订第2版,Marcel Dekker有限公司),第247-284页,公开了压制包衣壳的厚度通常在800到1200微米之间。而且这些作者指出“薄膜包衣的出现消除了干性包衣的许多优点,因为大量片剂可以在短时间内用溶解于有机或水性溶剂的薄膜形成剂包被。”通常,压制包衣必须包含大量的可压制物质。例如,WO 00/18447中的压制的壳使用了约30%的微晶纤维素。
有二种或更多不同部分的剂型在药学领域中可用于克服许多通常遇见的困难,包括分离不相容的活性成分,获得低剂量/高效活性成分的可接受的内容物一致性,以脉动形式传递一种或多种活性成分,对剂型的识别提供独特的美观特征。获得多部分的药物剂型的已知方法包括微粒包衣、多层片剂、压制包衣和喷雾包衣技术。例如在家用产品行业也知道用上述方法装配二种或多种不同部分的固体形式用来分离活性成分或在不同时间传递不同的活性成分。
包含包衣微粒的剂型如美国专利5,593,696描述的用于治疗胃疾患的口服剂型。该剂型包含的活性成分有法莫替丁和硫糖铝。在该剂型中,法莫替丁在组合物中以微粒(颗粒)形式存在,该微粒法莫替丁有保护屏障层以防止组合物中法莫替丁和硫糖铝相互反应。该屏障层是聚合物包衣较佳,该聚合物包衣在体内胃中部分溶解释放有包衣的法莫替丁。美国专利5,980,944描述了一种用于治疗胃肠道疾患的固体口服剂型,包括有效治疗剂量的适合治疗胃疾患的药物,该药物选自地芬诺酯、咯哌丁胺、咯哌丁胺-N-氧化物的颗粒,及它们药学上可接受的盐和它们的组合物,和治疗有效量的聚二甲基硅氧烷,其中药物和聚二甲基硅氧烷被颗粒上的对聚二甲基硅氧烷大体上不通透的屏障包衣所隔离。
所述的多层片剂,例如美国专利5,20,0193所描述的多层药物活性片剂,该片剂包含即时刻释放层和包含侵蚀促进剂的均一压制的持续释放层,使用时产生药物活性成分的持久续、缓慢和相对有规律增加的释放。美国专利6,372,252描述了一种药物持续释放制剂,该制剂能在人受试者给药后至少12小时提供治疗上有效的生物利用度的愈创木酚甘油醚。公开的改进释放愈创木酚甘油醚双层片剂有包含即时释放愈创木酚甘油醚制剂的第一部分和包含持续释放愈创木酚甘油醚制剂的第二部分。美国专利4,999,226公开了一种多层片剂,该片剂包含布洛芬层,吡啶基烷醇抗组胺层,和包含一层或多层的常规的药物赋形剂,该赋形剂散布在布洛芬和吡啶基烷醇层之间,用来在物理上分隔这两层。该多层片剂解决了与布洛芬和piperidino-alkanol抗组胺物之间物理上和化学不相容有关的问题。美国专利4,198,390描述了一种包含至少二种分离和不连续体积部分的片剂,其中一种包含聚二甲基硅氧烷,另一种包含抗酸剂。一个屏障分离二个体积部分以保持聚二甲基硅氧烷不与抗酸剂接触,防止聚二甲基硅氧烷从其片剂的体积部分移动到含有抗酸剂的体积部分,反之亦然。美国专利5,133,892描述了一个多层洗涤剂片剂,该片剂包含外层,屏障层和内层。该片剂有顺序地释放外层中包含的成分和内层中包含的成分。释放外层的成分和释放内层的成分之间的时间间隔是通过对屏障层成分的特殊选择和内层、屏障层和外层的相对厚度来控制的。该片剂能够随着不相容成分如酶和含氯漂白剂的分解而及时分离。该片剂还提供洗碟成分和漂洗助剂成分的有顺序的释放,使清洁在漂洗助剂释放之前完成。
压制包衣片剂用于分离不相容活性成分,和一种或多种活性成分的脉动释放。压制包衣的形状可以与片心的形状大体上不同,如WO 00/18447所公开的内容。商品化的压制包衣设备可由例如Korsch美国公司提供,它是Korsch AG的一个子公司,在WO 89/11968中有描述。通过压制制备的改进释放剂型在美国专利5,738,874和6,294,200,和WO 99/51209中有例子。通过压制包衣生产二部分的壳是可能的,该壳可以作为屏障或释放延迟包衣,但是压制包衣系统受到壳的厚度和壳的成分以及加工成本的限制。例如,Gunsel等的“压制包衣的片剂和层片剂”(Compression-coated and layer tablets),在H.A.Lieberman,L.Lachman,J.B.Schwartz编的《药物剂型-片剂》(Pharmaceutical Dosage Forms-Tablets)中(修订第二版,Marcel Dekker有限公司),第247-284页,公开了压制包衣壳的厚度通常在800到1200微米之间。而且这些作者指出“薄膜包衣的出现消除了干性包衣的许多优点,因为大量片剂可以在短时间内用溶解于有机或水性溶剂的薄膜形成剂包被。”通常,压制包衣必须包含大量的可压制物质。例如,WO 00/18447中的压制的壳使用了约30%的微晶纤维素。
一种解决低剂量/高效活性成分问题的方法在例如美国专利4,322,449和U.S.RE 31764所述,这些文件公开了制备药物的载体方法,该方法包含使用压电计量系统将液体的、溶解的或悬浮的活性物质在药物载体上打点。该公开方法使活性药物成分在药物载体上精确计量成为可能。打点是通过,例如,使用管状的或盘状的压电计量系统来实现的。然而,液体的、溶解的或悬浮的活性物质在通过使用高压的小喷嘴后,还可以被分成不连续的特定体积的小滴,由此各个小滴被依次施以电荷并断续地静电偏转向药物屏障。
把模塑部分掺入传递系统已用于家用产品行业,以获得更多的多功能性。组装形式包括已知如用于洗涤剂的传递的压制和模塑部分的混合物。WO 01/49815描述了一个用于洗碗机的组合物,该组合物的特征是片剂形式的基础组合物,该组合物在主要洗涤循环中大体上有活性,还有至少在片剂上有一个由洗碗机的漂洗循环中大体上有活性的物质组成的分离区。该组合形式的例子包括在主面上有半球状凹口的压制片剂部分,和与该压制片剂部分相配并附着于凹口的模塑球形部分。由于附着不恰当和二者间接触面极小而使两部分有分离倾向是该组装的一个缺点。在该组装中,模塑部分可比压制部分中的凹口小,例如,模塑部分的直径比压制部分中的开口直径至少小约20微米。另一方面,类似形式可用压配方法组装。在这些形式中,模塑部分的大小和压制部分中的凹口可以是相似的。这些组装还受到可能在界面上的几何学类型的限制。在压配的组装,模塑部分的在界面最深部分的宽度可以大体上不大于该模塑部分必须配合的开口宽度。换言之,压制部分的内外表面之间的锥度可以不是负数。而且,二部分接触的界面或区域可不形成交锁。
在设计药物剂型中另一个重要机会是产品的识别和区分。无论从消费者安全观点还是商业观点,有易于认识和识别的独特外形对剂型来说是有用的。
提供独特剂型识别的现有技术包括凹雕的使用。凹雕通常是通过蚀刻或印记图示来印下标记的,例如图形、标记、符号如字母、名称、标识图案、图示,等等,或它们的任何组合物,在片剂或其他固体剂型中,使用冲压步骤较佳。例如,美国专利5,827,535描述的软明胶胶囊有印记的图示在其外表面上。美国专利5,405,642公开了一种在白色或有色彩包衣片剂上突出凹雕的方法,通过在上述片剂上喷涂包含有不同色彩、蜡状物质和溶剂的充填物质的悬浮液,和除去溶剂和过量的充填物质和蜡状物质来实现。美国专利5,405,642的悬浮液包含蜡状物质和充填物质的临界重量比约1∶3到约1∶12。太少的蜡状物质会导致充填物质的结合不充分;太多的蜡状物质会使充填物质与片剂表面结合太牢,因而难以在以后除去。美国专利5,405,642的悬浮液的合适溶剂,其中充填物质,如果有的话,与染料不溶解。例如,非染色淀粉和纤维素可在酒精,如乙醇、异丙醇等等,卤化烃,如二氯甲烷、三氯甲烷等等中悬浮。
EP 060,023公开了一种在色彩(即,非白色)的固体物,在特殊片剂上强调凹雕的方法,通过对片剂表面包衣和用含有光学各向异性物质的包衣薄膜充填凹雕。获得了片剂表面和凹雕之间的光反差,可能是由于在片剂表面和凹雕的光学向异性物质的不同方向所致。该技术受到色彩物的限制,只能使用光学各向异性充填物质。仅基于不同反差获得的光学效果不是特别清楚。
EP 088,556涉及一种在白色或有色彩的片剂上强调凹雕的方法,通过将片剂表面颜色不同的干粉状物质与所述的片剂接触,除去没有沉积在凹雕中的过量粉状物质。粉状物质被认为在包衣片剂上凹雕的附着要好于在无包衣片剂上凹雕的附着。为了进一步增加附着,可使用蜡与粉状物质的混合物作为沉积物质并把充填的片剂加热到40℃到90℃以融化蜡。最后,可将外层包衣用到充填的片剂上。但是,EP 088,556公开的方法有许多问题。首先,粉状物质与凹雕的附着并不满意,因为该物质有松动和脱落的倾向。在将外层包衣用到充填的片剂上和松动的物质固定在外层包衣薄膜上,产生有斑点的片剂时此问题特别明显。另一方面,在粉状物质中添加蜡以提高附着性,使粉状物质更多的粘附在片剂表面而不利地影响粉状物质的分布和难以除去。在干粉状物质中使用蜡还带来其他一些缺点。特别是需要加热充填有蜡和粉状物质的片剂以熔化蜡带来了几乎不能接受的风险,因为许多药物是不耐热的,在过程中可能明显变坏。而且,在蜡和粉状物质的干混合物上均匀地染色也是困难的,这对有效的可能色彩组合物会有限制。
美国专利4,139,589描述了一种镶嵌片剂的制造过程,包括将持续释放的活性成分掺入到塑性口香糖物质中;将大体上即时释放药物活性成分掺入到非塑性片剂物质中;分别将口香糖物质和片剂物质转化成镶嵌片剂的片心和外层。一个较佳实施例包括将片剂物质转化为凹口的预制部件,将口香糖物质转化成片心,将片心插入到预制部件的凹口,将预制部件和片心导入片剂模具中,再对模具中的预制部件和片心进行压制。
上述产生有一个或多个分离部分的剂型的所有方法都比较昂贵、复杂和花费时间。而且,已知的生产充填凹雕的方法在合适的物质和作为结果而产生的剂型可获得的表面构型和外观受到限制。除了上述对充填物质本身的限制,片剂的包底衣必须是非粘着的,足以使充填物质在热包衣盘中翻动时被消除。这些方法不能产生充填物质高于片剂表面的充填凹雕,或甚至与片剂表面完全齐平的充填凹雕。现有技术产品只能提供相对于片剂表面轻微压低的、磨损的或凹陷的充填物质表面。
对医药工业来说,另一个明显的挑战是通过标准化最低限度降低生产和包装成本的机会。许多药物是几种不同强度的片剂,以方便有不同用药需要的不同患者。通常,较高强度片剂与含较少是活性成分的片剂相比更重和更大。通过设计多功能的剂型以在相同大小的片剂中容纳多个不同剂量的药物,可降低操作成本和包装成本,而患者和医学保健专业人士在同一性和强度方面容易识别。
因此,本发明的目的之一是提供一种组合形式,该形式包含至少一种活性成分,第一部分和第二模塑部分包含第二种物质,其中该第二种物质是镶嵌的与第一种物质在成分上不同。
由本文详细描述提供的本发明的其他目的、特征和优点对本领域中的熟练技术人员是明显的。
发明概要
在一个实施方案中,本发明的剂型包含至少一种活性成分,第一部分包含一个外表面和一个或多个定义为至少一个有凹口的内表面的腔,和外表面,和镶嵌在第一部分的腔内和有外表面的第二模塑部分。第一和第二部分在界面上相接触,第二部分包括凝固的热塑性物质,第二部分大体上共形地存在于凹口上。
在另一个实施方案中,第二模塑部分大体上没有直径在0.5到5.0微米的孔。
在另一个实施方案中,第一和第二部分在界面上紧密接触。
在另一个实施方案中,第一部分是压制的片剂。
在另一个实施方案中,第一部分是模塑的片剂。
在另一个实施方案中,第一部分包含凹雕,第二部分在凹雕中。
在另一个实施方案中,第二部分的外表面与第一部分的外表面齐平。
在另一个实施方案中,第二部分的外表面相对于第一部分的外表面是升高的。
在另一个实施方案中,第一部分基本上由单一均质层组成。
在另一个实施方案中,第二模塑部分包括至少一种活性成分。
在另一个实施方案中,第一部分有第一种颜色,镶嵌的第二部分有第二种颜色。
在另一个实施方案中,第一部分包含第一活性成分和镶嵌的第二部分包含与第一活性成分相同或不同的第二活性成分。
在另一个实施方案中,第一和第二部分一起构成预先安排的式样。
在另一个实施方案中,第一部分包含微电子装置。
在另一个实施方案中,第一部分中一个或多个腔的内表面的锥度值小于零。
在另一个实施方案中,界面与内表面大体上同等延伸。
在另一个实施方案中,第一部分是不连续的,第二部分是连续的。
在本发明的另一个实施方案中,剂型包含至少一种活性成分,片心有外表面,壳至少在片心外表面的一部分上。壳包含第一壳部分和第二壳部分,第二模塑壳部分镶嵌入第一模塑壳部分,第一和第二壳部分在界面上接触。
在另一个实施方案中,壳有外表面,第二模塑壳部分从片心的外表面延伸到壳的外表面。
在另一个实施方案中,第一和第二壳部分都是不连续的。
在另一个实施方案中,第一壳部分是不连续的,第二壳部分是连续的。
在另一个实施方案中,第一壳部分有第一色彩,第二壳部分有第二色彩。
在另一个实施方案中,片心包含压缩的粉剂。
在另一个实施方案中,片心包含插入物。
在另一个实施方案中,插入物包含一种活性成分。
在另一个实施方案中,一个或多个片心、镶嵌部分或插入物包含一种活性成分。
在另一个实施方案中,片心包含微电子装置。
在另一个实施方案中,插入物包含微电子装置。
在另一个实施方案中,第一壳部分、第二壳部分,或两者有带纹理的外表面。
在另一个实施方案中,壳的外表面包含预先安排的式样。
在另一个实施方案中,壳包含在其中的一个或多个开口。
在另一个实施方案中,壳的外表面大体上光滑。
在另一个实施方案中,壳包括凹口、字母、符号或图案。
在另一个实施方案中,第一壳部分包括凹口、字母、符号或图案。
在另一个实施方案中,第二壳部分包括凹口、字母、符号或图案。
在另一个实施方案中,第一壳部分、第二壳部分,或两者包含以字母、符号或图案形式的突起部分。
在另一个实施方案中,镶嵌部分大体上没有直径0.5到5.0微米的孔。
在另一个实施方案中,第二壳部分有界面的锥度值小于零的部分。
在本发明的另一个实施方案中,剂型包含至少一种活性成分、片心、和有不连续的第一模塑壳部分的壳,和连续的第二模塑壳部分,第一壳部分的不连续是由于第二模塑壳部分的存在,第一和第二壳部分在成分上不同。
在另一个实施方案中,第一和第二壳部分包括凝固的热塑性物质。
在另一个实施方案中,第一和第二壳部分的外表面是共线性的。
在另一个实施方案中,第二模塑部分有锥度值小于零的部分。
在另一个实施方案中,腔确定为许多用于容纳镶嵌部分的侧壁,该侧壁有小于零的锥度值。
在另一个实施方案中,第一壳部分、第二壳部分,或是两者包含活性成分。
附图的简要说明
图1A和1B显示了本发明的剂型的一个实施例。
图2A和2B显示了本发明的剂型的另一个实施例,其中片心有包含镶嵌部分的壳。
图3A和3B显示了现有技术组合物的锥度和本发明的一个实施方案。
发明的详细描述
在本发明的一个实施方案中,剂型包含至少一种活性成分,第一部分包含一个或多个腔和凹口和一个外表面,第二模塑部分镶嵌入第一部分的腔内和有一个外表面。第一和第二部分在界面上接触,第二部分包括凝固的热塑性物质,第二部分大体上共形地在第一部分的凹口上。
本文中使用的,一个部分的“外表面”是指包含完成的剂型的外表面部分的表面。
本文中使用的术语“大体上共形地”是指第一部分的腔由具峰和谷的表面确定,第二部分在腔内,第二部分的表面也有峰和谷,第二部分的表面的峰和谷与腔确定的表面的主要峰和谷大体上相反。
在本发明的另一个实施方案中,剂型包含至少一种活性成分,片心有外表面,壳至少在片心外表面的一部分上,其中壳包含第一壳部分和第二壳部分,第二模塑壳部分镶嵌入第一模塑壳部分中。
在本发明的另一个实施方案中,剂型包含至少一种活性成分、片心、和有不连续的第一模塑壳部分的壳,和连续的第二模塑壳部分,第一壳部分的不连续是由于第二模塑壳部分的存在,第一和第二壳部分在成分上不同。
本文中使用的术语“成分上不同”是指通过定性或定量化学分析、物理测试或视觉观察易于区分的特征。例如,第一和第二物质可包含不同的成分,或不同水平的相同成分,或第一和第二物质可有不同的物理或化学特性、不同的功能特性或在视觉上可区分。可不同的物理或化学特性的例子包括亲水性、疏水性、吸湿性、弹性、塑性、抗拉强度、结晶性和密度。可不同的功能特性的例子包括物质本身或其中活性成分溶出的速度和/或程度,物质崩解的速度,活性成分的渗透性,对水或液体介质的渗透性,等等。视觉上区分的例子包括大小、形状、地形或其他几何特征、色彩、色调、不透明性和光泽。
在某些实施方案中,第一部分基本上由单一均质层组成。换句话说,可以是单一模塑组合物或单一压制片剂。若该部分被分成几个部分,每个部分有相同的密度、多孔性、色彩、结晶性等。
本文中使用的术语“剂型”应用于任何固体物体、半固体或液体组合物,设计含有某些成分的特别预先确定量(即剂量),例如下文中确定的活性成分。合适的剂型可以是给药系统,包括口服、含服给药、直肠给药、局部、透皮或粘膜传递,或皮下植入,或其他植入的给药系统;或用于传递矿物质、维生素和其他营养食品,口腔护理制剂、食用香料等等的成分。本发明的剂型被认为是固体较佳,虽然它们可包含液体或半固体成分。在较佳实施例中,剂型是在人胃肠道中释放药物活性成分的口服给药系统。在另一个较佳实施例中,剂型是包含药物非活性成分的口服“安慰剂”给药系统,剂型的设计成如特定药物活性剂型相同的外观,如可用于临床研究中的对照来测试,例如,特定药物活性成分的安全性和功效。
本发明使用的合适的活性成分包括如药物、矿物质、维生素和其他营养食品、口腔护理制剂、食用香料和它们的混合物。合适的药物包括止痛药、抗炎剂、抗关节炎药、麻醉剂、抗组胺药、镇咳药、抗生素、抗感染药、抗病毒药、抗凝剂、抗抑郁药、抗糖尿病药、镇吐药、抗气胀药、抗真菌药、解痉药、食欲抑制剂、支气管扩张药、心血管制剂、中枢神经系统制剂、中枢神经系统兴奋剂、减轻充血剂、利尿剂、祛痰药、胃肠道制剂、偏头痛制剂、晕动病产品、粘液溶解剂、肌肉松驰剂、骨质疏松症制剂、聚二甲基硅氧烷、呼吸制剂、助眠剂、泌尿道制剂和它们的混合物。
合适的口腔护理制剂包括呼吸清新剂、牙齿增白剂、抗微生物剂、牙齿矿化剂、龋齿抑制剂、局部麻醉剂、粘膜保护剂等等。
合适的食用香料包括薄荷脑、薄荷、薄荷香料、水果香料、巧克力、香草、口香糖香料、咖啡香料、液体香料和组合物等等。
合适的胃肠道制剂的例子包括抗酸药如碳酸钙、氢氧化镁、氧化镁、碳酸镁、氢氧化铝、碳酸氢钠、二羟铝碳酸钠;剌激性轻泻药如吡沙可啶、波希鼠李皮、二羟蒽醌、番泻叶、酚酞、芦荟、蓖麻油、蓖麻油酸和脱氢胆酸及它们的混合物;H2受体拮抗剂如法莫替丁、雷尼替丁、西米替丁、尼扎替丁、质子泵抑制剂如奥美拉唑或兰索拉唑;胃肠道细胞保护剂如硫糖铝和米索前列醇;胃肠道促动药如普卡比利,针对幽门螺杆菌的抗生素如克拉霉素、阿莫西林、四环素和甲硝唑;止泻药如地芬诺酯和洛哌丁胺;葡萄糖吡咯;镇吐药如昂丹司琼;镇痛药如美沙拉明。
本发明的一个实施方案中,活性剂可选自吡沙可啶、法莫替丁、雷尼替丁、西米替丁、普卡比利、地芬诺酯、洛哌丁胺、乳糖酶、美沙拉明、铋、抗酸药和药学上可接受的盐、酯、异构体和它们的混合物。
在另一个实施方案中,活性剂可选自镇痛药、抗炎剂和解热药,如非甾体类抗炎药(NSAIDs),包括丙酸衍生物,如布洛芬、萘普生、酮洛芬等等;醋酸衍生物,如吲哚美辛、双氯芬酸、舒林酸、托美汀等等;芬那酸衍生物,如甲芬那酸,甲氯灭酸、氟芬那酸等等;二苯基酸酸衍生物,如二氟尼柳,氟苯柳,等等;和昔康类制剂,如吡罗昔康,舒多昔康,伊索昔康,美洛昔康等等。在一个较佳实施方案中,活性剂可选自丙酸衍生物NSAID,如布洛芬、萘普生、氟比洛芬、芬布芬、非诺洛芬、吲哚洛芬、  酮洛芬、氟洛芬、吡洛芬、卡洛芬、奥沙普嗪、普拉洛芬、噻丙芬和药学上可接受的盐、衍生物和它们的组合物。在本发明的另一个实施方案中,活性剂可选自对乙酰氨基酚、乙酰水杨酸、布洛芬、萘普生、酮洛芬、氟比洛芬、双氯芬酸、环苯扎林、美洛昔康、罗非昔布、塞来昔布和药学上可接受的盐、酯、异构体和它们的混合物。
在本发明的另一个实施方案中,活性剂可选自假麻黄碱、去甲麻黄碱、氯苯那敏、右美沙芬、苯海拉明、艾司咪唑、特非那定、非索非那定、洛罗塔丁、地氯雷他定、doxilamine、去甲阿司咪唑、西替利嗪、它们的混合物和药学上可接受的盐、酯、异构体和它们的混合物。
合适的聚二甲基硅氧烷的例子,包括但不限于二甲硅油和西甲硅油,由美国专利4,906,478;5,275,822;和6,103,260公开,每个文件的内容被本文清楚的纳入作为参考。本文中使用的术语“二甲基硅油”指的是聚二甲基硅氧烷的大类,包括但不限于二甲硅油和二甲基硅油。
有效治疗量的剂型中可有一种或几种活性成分,该量通过口服获得需要的治疗反应,易被本领域熟练技术人员确定。如本领域所知,为确定该量,必须考虑使用的特定活性成分,该活性成分的生物利用度特征,剂量方案,病人的年龄和体重和其他因素。在一个实施方案中,该剂型包括至少约85重量百分比的活性成分。
在某些实施方案中,需要活性成分的改进释放,如本领域所知,该活性成分可任选地用释放改进包衣包被。这对改进剂型中活性成分的释放曲线有利的提供了另外的工具。例如,如本领域所知,剂型可包含一种或多种活性成分的包衣微粒,其中微粒包衣起释放改进功能。对微粒合适的释放改进包衣的例子在美国专利4,173,626;4,863,742;4,980,170;4,984,240;5,286,497;5,912,013;6,270,805;和6,322,819中有描述。
可以使用商品化的改进释放活性成分。例如,本发明可通过凝聚加工用释放改进聚合物包裹对乙酰氨基酚颗粒。凝聚包裹的乙酰氨基酚可以从Eurand美国公司(Vandalia,Ohio)或Circa有限公司(Dayton,Ohio)商业购买。
如果活性成分有讨厌的味道,和该剂型被用来咀嚼或在吞咽前在口腔中崩解的,该活性成分可用味觉掩蔽包衣法包被,这在本领域是已知的。合适的味觉掩蔽包衣法的例子在美国专利4,851,226;5,075,114和5,489,436中描述。也可使用商品化的味觉掩蔽的活性成分。例如,本发明可通过凝聚加工用乙茎纤维素和其他聚合物包裹对乙酰氨基酚颗粒。凝聚包裹的乙酰氨基酚可以从Eurand美国公司(Vandalia,Ohio)或Circa有限公司(Dayton,Ohio)商业购买。
在第一部分是通过压制制备的实施方案中,合适的赋形剂包括充填剂、粘合剂、崩解剂、润滑剂、助流剂等等。
在第一部分是通过压制制备的实施方案中,合适的充填剂包括水溶性可压的碳水化合物如糖,包括葡萄糖、蔗糖、异麦芽果糖、果糖、麦芽糖和乳糖;聚葡萄糖,糖醇类,包括甘露醇、山梨醇、异麦芽、麦芽糖醇、木糖醇、赤藓糖醇、淀粉水解物,包括糊精和麦芽糖糊精等等;不溶水塑性变形物质,如微晶纤维素或其他纤维素衍生物;水不溶性脆性破裂物质,如磷酸二钙、磷酸三钙等等及它们的混合物。
在第一部分是通过压制制备的实施方案中,合适的粘合剂包括干粘合剂如聚乙烯吡咯烷酮、羟丙甲基纤维素等等;湿粘合剂如水溶性聚合物,包括水胶体如藻酸盐、琼脂、瓜尔胶、剌槐豆、角叉菜胶、他拉胶、阿拉伯树胶、黄芪胶、果胶、黄原胶、吉兰糖胶、麦芽糊精、半乳糖甘露聚糖、pusstulan、昆布多糖、硬葡聚糖、阿拉伯树胶、菊粉、果胶、whelan、rhamsan、zooglan、methylan、壳多糖、环糊精、脱乙酰壳多糖、聚乙烯吡咯烷酮、纤维素、淀粉等等;及它们的衍生物和混合物。
在第一部分是通过压制制备的实施方案中,合适的崩解剂包括羟基乙酸淀粉钠、交联聚乙烯吡咯烷酮、交联羧甲基纤维素、淀粉、微晶纤维素等等。
在第一部分是通过压制制备的实施方案中,合适的润滑剂包括长链脂肪酸和它们的盐,如硬脂酸镁和硬脂酸、滑石粉和蜡。
在第一部分是通过压制制备的实施方案中,合适的助流剂包括胶体二氧化硅等等。
在第一部分是通过压制制备的实施方案中,本发明的剂型也可掺入药学上可接受的辅剂,包括,例如,防腐剂、高强度甜味剂如阿斯巴坦、乙酰舒洗钾、环磺酸盐、糖精、三氯半乳蔗糖等等;其他甜味剂如dihydroalcones、甘草甜素、MonellinTM、甜菊苷、TalinTM等等;调味剂,抗氧化剂,表面活性剂和着色剂。
当与液体如水、胃酸、肠液或等等接触时,活性成分或成分最好能够溶出。在一个较佳实施方案中,活性成分的溶出特性符合USP对含有活性成分的即时释放片剂的技术要求。在需要活性成分被吸收入动物的体循环的实施方案中,活性成分或成分在接触液体如水、胃液、肠液等等时最好能够溶出。在一个实施方案中,活性成分的溶出特性符合USP对含有活性成分的即时释放片剂的技术要求。例如,对乙酰氨基酚片剂,USP24要求在PH5.8磷酸缓冲液中,使用USP装置2(桨式)在50rpm下,在给药后30分钟内至少有剂型中包含的80%对乙酰氨基酚被释放,而对布洛芬片剂,USP24要求在PH7.2磷酸缓冲液中,使用USP装置2(桨式)在50rpm下,在给药后60分钟内至少有剂型中包含的80%布洛芬被释放。见USP24,2000版,19-20和856(1999)。在另一个实施方案中,活性成分的溶出特性被改进:如控制的、持续的、延长的、延迟的、长期的、时延的等等。
对本发明的剂型的总体理解可参照图1A,1B,2A和2B。图1A和1B显示了本发明的剂型的一个实施方案。在图1A中,显示包括第一部分4的剂型2。第一部分包含许多凹陷,依次包含镶嵌的第二部分6。在这个实施方案中,第一活性成分位于第一部分4内,第二活性成分位于镶嵌的第二部分6内。图1B是图1A的剂型2的截面图。如图1B所示,在这个实施方案中,模塑的镶嵌第二部分6从第一表面8和第二表面10部分延伸到第一部分4。在这个实施方案中,第一活性成分位于镶嵌的第二部分6内,第二活性成分(可与第一活性成分相同或不同)位于第一部分4内,虽然在其他实施方案中只有在镶嵌的第二部分6或第一部分4中的一个包含活性成分。
在图1A和1B所示的其他实施方案中,清楚或半透明的包衣可在第一表面8和第二表面10上。
图2A和2B显示了本发明的另一个实施方案。图2A显示包含片心104的剂型102。该片心的壳105至少在片心104的外表面的一部分上。壳105在图2B中有详细显示,该图是图2A的剂型的截面图。如图2B所示,壳105在片心104的外表面108和110上,该壳包含有腔的第一壳部分107,模塑的镶嵌的第二壳部分106在腔内。在这个实施方案中,第一活性成分位于壳部分107内,第二活性成分位于镶嵌的第二壳部分106内,虽然在其他实施方案中只有在第一壳部分107或镶嵌的第二壳部分106中的一个可包含活性成分。片心104也可任选地包含一种活性成分,该活性成分可以与第一壳部分107和镶嵌的第二壳部分106所包含的活性成分相同或不同。如图2B所示,壳105可沿着片心104的侧面部分112和114延伸,镶嵌部分116和118可在壳105的凹口内。在这个实施方案中,腔通过第一壳部分延伸到片心的表面;但是,在其他实施方案中腔只通过第一壳部分的一部分延伸。
片心(或基质)可以是任何固体或半固体形式。片心可通过任何合适的方法制备,例如和可以是压制的剂型,或是模塑的。  本文中使用的“基质”指一个表面或下面的支持物,其他物质位于它上面或与它作用,“片心”是指至少被其他物质部分包裹或围绕的物质。为了本发明的目的,术语可以互换:即术语“片心”也可用来指“基质”。  片心由固体组成较佳,例如,片心可以是压制或用模塑的片剂、硬或软胶囊、栓剂,或糖膏剂形式如糖锭、牛轧糖、焦糖、软糖或脂基成分。在某些其他实施方案中,在完成的剂型中片心可以是半固体或液体形式。
片心可以是许多不同的形状。例如,在一个实施方案中,片心的形状可以是截短的锥体。在另一个实施方案中,片心的形状可以是多面体,如立方体、角锥体、棱柱体等等;或可以有一些非平面的空间构形的几何形状,如圆锥体、圆柱体、球体、圆枕体等等。可使用的示范性片心形状包括如“伊丽莎白公司片剂设计培训手册”(The Elizabeth Companies Tablet Design Training Manual)(ElizabethCarbide Die Co.,Inc.,)第7页(McKeesport,Pa.)(本文引入作为参考)描述的压制工具制成的片剂形状,具体如下(片剂形状与压制工具的形状正好相反):
1.浅凹面
2.标准凹面
3.深凹面
4.特深凹面
5.修饰的球凹面
6.标准凹面平分
7.标准凹面双倍平分
8.标准凹面欧洲平分
9.标准凹面部分平分
10.双半径
11.斜面和凹面
12.平面
13.平面对斜边(F.F.B.E.)
14.平面对斜边(F.F.B.E.)平分
15.平面对斜边(F.F.B.E.)双倍平分
16.环形
17.小凹
18.椭圆
19.卵形
20.囊状
21.矩形
22.正方形
23.三角形
24.六角形
25.五角形
26.八角形
27.菱形
28.箭头形
29.弹头形
30.筒形
31.半月形
32.盾形
33.心形
34.杏仁形
35.家用盘形
36.平行四边形
37.不规则四边形
38.图形8/杠铃形
39.蝶形领结形
40.不等边三角形
片心或底片心(Subcore)可任选地至少部分被压制的、模塑的、或喷雾的包底衣覆盖。但是,在一个较佳实施例中,片心可以大体上没有包底衣:即在片心的外表面和壳的内表面之间没有包底衣。
在本发明的另一个实施例中,片心是压制的剂型,如粉剂压制成的片剂。该粉剂包含活性成分较好,可任性地包含各种赋形剂,如常规的粘合剂、崩解剂、润滑剂、填充剂等等,或该粉剂可包含其他药物或非药物性质的颗粒,如压片的非活性安慰剂混合物,糖膏剂混合物等等。一种特别制剂包括活性成分、粉末蜡(如虫胶蜡、微晶蜡、聚乙二醇等等),可任选地包括崩解剂和润滑剂,详细可见未定的美国专利申请序列号09/966,493的第4到11页,本文引入作为参考。
片心可任选地包括底片心(也可被称为“插入物”),片心可用任何方法制造,例如,压制或模塑,也可任选地包括一种或多种活性成分。
本发明的一个实施方案中,本发明的各种剂型包含由粉剂混合制成的片心,该粉剂的平均粒径约50微米到500微米。在一个实施方案中,活性成分的平均粒径约50微米到500微米。在另一个实施方案中,至少一种赋形剂的平均粒径约50微米到500微米。在上述实施方案中,一种主要的赋形剂,即包含片心重量至少50%的赋形剂,其平均粒径约50微米到500微米,例如约100微米到约500微米在这个大小范围内的微粒对直接压制加工特别有用。在本发明的一个较佳实施方案中,片心可以通过直接压制过程制备。
在本发明的一个这种实施方案中,片心是直接压制的片剂,该片剂由大体上不含水溶性聚合物粘合剂和水合的聚合物的粉剂制成。该组合物有利于维持即时释放溶出曲线,最低程度降低加工和材料成本和提供剂型最佳的物理和化学稳定性。
在片心是通过直接压制制备的实施方案中,该包含片心的物质,如活性成分或成分和赋形剂混合在一起,作为干粉剂较佳,加到应用压力的设备中制成片心。可以使用任何合适的压制设备,包括如辊式压实机如chilsonator或落下辊;或常规的压片机。通过本领域已知的旋转压片机压实形成该片心较佳。在旋转压片机中,计量体积的粉剂填入模腔中,该压片机作为“压模辊道”的一部分在充填位置和压实位置之间旋转,在该压实位置粉剂在上下冲头之间被压实,至弹出位置制成的片剂被下冲头从模腔推出。直接压制加工能最低程度地减少或消除水溶性非糖类聚合物粘合剂如聚乙烯吡咯烷酮、藻酸盐、羟丙基纤维素、羟丙甲基纤维素、羟乙基纤维素等等,它们对溶出有不利影响。
在一个较佳实施方案中,通过使用待批美国专利申请系列号09/966,509,第16-27页所述的压制方法和设备制备片心,本文引入作为参考。特别地,该片心是使用旋转压制模件制造的,该模件包含充填区、插入区、压制区、弹出区和清除区在如美国专利申请系列号09/966,509的图6所示的有双排模具结构的单一设备中。压制模中的模具使用真空辅助充填较佳,其过滤器位于或靠近每个模具。压制模件的清除区包含任选的粉剂回收系统以从过滤器中回收多余粉剂并将粉剂还回模具中。
在另一个实施方案中,通过湿制粒法制备该片心,在该方法中活性成分或成分、合适的赋形剂、湿粘合剂的溶液或分散体(如水煮淀粉糊或聚乙烯吡咯烷酮溶液)混合并被制成粒状。湿制粒法适用的设备包括低剪床,如行星搅拌器、高剪床搅拌器和液体床,包括旋转流化床。制成的粒状物质被烘干,任选地与其他成分干混合,如辅剂和/或赋形剂如润滑剂、着色剂等等。最后的干混合适合用前述段落描述的方法压制。
直接压制和湿制粒法加工是本领域已知的,详细记述于,如,Lachman等的《工业制药的理论和实践》(The Theory and Practice of Industrial Pharmacy),11章(第3版,1986)。
在一个实施方案中,第一部分和片心可以用如待批的美国专利申请系列号09/966,450,第57-63页所述的热凝固成型方法和设备制备,本文引入作为参考。在这个实施方案中,将流动形式的始料注入成型室形成该第一部分和片心。该始料包括活性成分和热凝固物质较佳,温度在热凝固物质的熔点之上但在活性成分的分解温度之下。始料在成型室中冷却并凝固成为有形状的片心(即有模具的形状)。
在另一个实施方案中,第一部分和片心可以用如待批的美国专利申请系列号09/966,497,第27-51页所述的热循环成型方法和设备制备,本文引入作为参考。在这个实施方案中,将流动形式的始料注入加热的成型室形成该第一部分和片心。该始料包括活性成分和热塑性物质较佳,温度在热塑性物质的固定温度之上但在活性成分的分解温度之下。始料在成型室中冷却并凝固成为有形状的片心(即有模具的形状)。
按照这个方法,始料必须是流动形式。例如,它可以包含悬浮在熔化基质中的固体微粒,如聚合物基质。始料可以是完全熔化或处于糊状形式。始料可以包含溶解在熔化物质中的活性成分。另一方面,始料可通过在溶剂中溶解固体制备,该溶剂在始料熔化后从始料中蒸发。
该始料可以包含任何需要掺入有形状形式的可食用物质,包括活性成分如上述关于片心、营养剂、维生素、矿物质、调味剂、甜味剂等等的活性物质。该始料包含活性成分和热凝固物质较佳。该热凝固物质可以是在约37℃到约250℃温度间能流动的任何可食用物质,和在约-10℃到约35℃温度间是固体或半固体的物质。该能流动的物质可以是在约37℃到约250℃温度间任何可食用物质,和在约-10℃到约35℃温度间是固体、半固体或可形成凝胶的物质。当处于液体或流动状态时,流动物质可包含溶解或熔化的成分,和任选地包含溶剂例如水或有机溶剂,或它们的组合物。该溶剂可通过烘干被部分或大体上除去。合适的流动物质包括那些包含热凝固物质、薄膜形成聚合物、胶凝聚合物、水胶体、低熔点疏水物质如脂肪和蜡、非结晶碳水化合物等等。较佳的热凝固物质包括水溶性聚合物如聚二醇、聚环氧乙烷和衍生物和蔗糖酯;脂肪如可可油、氢化植物油如棕榈仁油、棉籽油、向日葵油和大豆油;游离脂肪酸和它们的盐;甘油一酯、甘油二酯、甘油三酯、磷脂,蜡如巴西棕榈蜡、鲸蜡、蜂蜡、小烛树蜡、虫胶蜡、微晶蜡和石蜡;含脂肪混合物如巧克力;糖如用于制造硬糖形式的无定形玻璃状的糖,如用于制造软糖形式的过饱和溶液中的糖;低湿度聚合物溶液如明胶和其他水胶体的混合物,该混合物的水分达约30%,如用于制造“gummi”糖膏剂形式一样。在一个较佳实施方案中,热凝固物质是脂肪和甘油一酯、甘油二酯的混合物。
在另一个实施方案中,该片心可以是中空的或抽空的片心。例如,该片心可以是空的胶囊壳。两者择-地,中空片心可以通过用模塑制备。在这种方法中,流动物质被注入模腔中,该腔的温度达到片心的外表面(与模具相接触)开始变硬或凝固。然后使用合适的装置把多余的流动物质从片心的中心抽取,例如用活塞泵。在另一个方法中,空胶囊用作底片心,在其上用本领域已知的方法形成包衣层,如喷雾包衣、浸渍包衣或热循环成形方法,如待批的美国专利申请系列号09/966,497,第27-51页所述,本文引入作为参考。
在本发明的某些实施方案中,片心还可包含用任何方法获得的包底衣,例如喷雾、压制或模塑。在本发明的某些其他实施方案中,片心可以大体上没有包底衣。
本发明的另一个实施方案中,片心至少部分包含一种或多种插入物。插入物可被制成任何形状或大小。例如,可制成不超过一个对称轴的不规则形状插入物。也可制成圆柱形插入物。插入物可使用常规的技术如用盘制(Panning)、压制或模塑制备。在一个实施方案中,插入物可使用本文所述的热凝固方法和设备制备。
本发明的一个实施方案中,插入物的平均直径约100微米到约1000微米。本发明的另一个实施方案中,插入物的平均直径或厚度可以是片心的直径或厚度的约10%到约90%。本发明的另一个实施方案中,片心可以包含许多插入物。
在另一个实施方案中,插入物的平均直径、长度或厚度大于片心的直径或厚度约90%,例如,插入物的平均长度大于片心的厚度约100%。
在本发明的另一个实施方案中,片心、插入物(如果使用的话)、镶嵌部分或它们的任何组合物可以包含微电子装置(如电子“芯片”),该微电子装置可用作活性部件或用来控制,例如,对输入信号响应的片心或插入物内活性成分的释放速度。该微电子装置的例子如下:
(1)整体的,自身调节响应的治疗装置包括生物传感器,电子反馈和完全整体的药物/对抗释放装置。这些装置排除遥测试和人为干涉,例如在www.chiprx.com/products.html所公开的内容,本文引入作为参考。
(2)小型化诊断成像系统包含可吞咽的含有视频照相机的胶囊,例如在www.givenimaging.com/usa/default.asp所公开的内容,本文引入作为参考。
(3)皮下葡萄糖监控器包括植入式或插入式传感器装置,该装置检测肠液内葡萄糖浓度变化,并与外部的探测器和数据储存设备连通。例如,该装置在www.applied-medical.co.uk/glucose.htm公开,本文引入作为参考。
(4)密封在人工眼内晶状体的微显示视觉辅助装置。该装置包括用于能量供应的接收器、数据和时钟恢复,和连接于硅CMOS驱动电路和微光学设备上的小型化LED阵列倒装芯片,例如,在 http://ios.oe.uni-duisberg.de/e/公开,本文引入作为参考。该微显示装置从放置在眼外的高动力范围CMOS照相机接收位流+能量无线信号,该照相机产生数字黑白图象并通过数字信号处理单元(DAP)用接近1Mbit/s的数据速度转换成一系列位流。该图象被投射到视网膜上。
(5)微芯片用于刺激受损的视网膜细胞,使它们对黄斑变性或其他视网膜疾患的患者的大脑发送视觉信号。该芯片为2毫米×25微米,含有近5,000个极小的太阳能电池(“微光二极管”),每个都有自己的刺激电极。这些微光二极管把图象的光能量转换成电化学脉冲,刺激AMD和RP患者中视网膜残存的功能性细胞。该微芯片在www.optobionics.com/artificialretina.htm公开,本文引入作为参考。
(6)一次性“灵敏针头”用于乳房活组织检查,能实时显示结果。该装置装入连接到电子计算机的20到21规格的一次性针头,随针头插入到可疑的病变部位。该装置测量氧部分压力、电阻抗、温度,和光散射和吸收特性包括脱氧血红蛋白、血管化和组织密度。由于来自六路同时测量的准确性,和该装置的实时特性,该装置有希望超过片心心针头活组织检查步骤的准确性水平和接近外科手术活组织检查的高精确水平。而且,如果发现癌症,可配置该装置以进行不同的治疗如癌症标记、激光加热、低温、药物、和放射性籽壳。该装置在www.biolnminate.com/description.html公开,本文引入作为参考。
(7)个人UV-B记录器,用于测量和记录UV-B暴露的分级装置,可配置在腕表面上。该装置也可作用做眼罩佩戴。
在本发明的一个实施方案中,壳与镶嵌部分或二者由流动性物质制成。
镶嵌部分必须是模塑的。在本发明的一个较佳实施实施方案中,镶嵌部分是使用上述的热凝固成型或热循环成型方法制备的。
本发明的镶嵌部分可包含任何可模塑的物质,包括例如,膜形成剂、低熔点疏水物质、胶凝聚合物、增稠剂、增塑剂、辅剂和赋形剂。
在一个实施方案中,镶嵌部分最好包含至少约50%,较佳至少约80%,最佳至少约90%的物质,选自膜形成剂、胶凝聚合物、低熔点疏水物质、非结晶性糖或糖类醇,和它们的混合物。在另一个实施方案中,镶嵌部分包含至少约50%,较佳至少约80%,最佳至少约90%的物质,选自膜形成剂、胶凝聚合物、低熔点疏水物质,和它们的混合物。
在本发明的一个实施方案中,流动物质包含作为胶凝聚合物的明胶。明胶是一种天然的热胶凝聚合物。它是通常溶于温水的白蛋白类的衍生蛋白的无色无味混合物。通常使用的明胶有两种类型-A型和B型。A型明胶是酸处理的原料的衍生物。B型明胶是碱处理的原料的衍生物。明胶的水分含量,和Bloom强度、成分与原始明胶加工条件,决定了它在液体和固体之间的转换温度。Bloom是明胶凝胶体强度的标准量度,它与分子量有粗略的关系。Bloom被定义为以克为重量单位的用来在保持10℃、17小时的6.67%明胶凝胶中移动直径为半英寸的塑料活塞4毫米所需的力。在一个较佳实施例中,流动物质包含20%275 Bloom猪皮明胶,20%250Bloom骨明胶,和大约60%水的水溶液。
其他较佳的流动物质可包含蔗糖-脂肪酸酯;脂肪如可可油、氢化植物油如棕榈仁油、棉籽油、向日葵油和大豆油;游离脂肪酸和它们的盐;甘油一酯、甘油二酯、甘油三酯、磷脂,蜡如巴西棕榈蜡、鲸蜡、蜂蜡、小烛树蜡、虫胶蜡、微晶蜡和石蜡;含脂肪混合物如巧克力;糖如用于制造硬糖形式的无定形玻璃杯中的糖,如用于制造软糖形式的过饱和溶液中的糖;碳水化合物如糖醇(例如山梨醇、麦芽糖醇、甘露醇、木糖醇和赤藓糖醇),或热塑性淀粉;低湿度聚合物溶液如明胶和其他水胶体的混合物,该混合物的水分达约30%,如用于制造“gummi”糖膏剂形式一样。
在本发明的一个较佳实施例中,流动物质可包含薄膜形成剂如纤维素酯,例如羟丙甲基纤维素或改性淀粉,例如蜡状玉米淀粉;任选的膨胀剂如多聚碳水化合物,例如麦芽糊精;任选的增稠剂如水胶体,例如黄原胶或角叉菜胶,或糖,例如蔗糖;任选的增塑剂,例如聚乙二醇、丙二醇,植物油如蓖麻油、甘油,和它们的混合物。
本领域中已知的任何薄膜形成剂适合用于流动物质。合适的薄膜形成剂的例子包括但不限于聚乙烯醇(PVA)、聚乙烯吡咯烷酮(PVP)、羟丙基淀粉、羟乙基淀粉、支链淀粉、甲乙基淀粉、羧甲基淀粉、甲基纤维素、羟丙基纤维素(HPC)、羟乙甲基纤维素(HMEC)、羟丙甲基纤维素(HPMC)、羟丁甲基纤维素(HBMC)、羟乙乙基纤维素(HEEC)、羟乙羟丙甲基纤维素(HBMPMC)、甲基丙烯酸和甲基丙烯酸酯共聚物、聚环氧乙烷和聚乙烯吡咯烷酮共聚物、明胶、蛋白质如乳清蛋白、可凝固蛋白质如白蛋白、酪蛋白和酪蛋白分离物、大豆蛋白和大豆蛋白分离物、预胶凝化淀粉,及它们的聚合物和衍生物和混合物。
一种合适的羟丙甲基纤维素化合物是“HPMC2910”,其纤维素醚的置换度约1.9,羟丙基的摩尔置换度为0.23,按照化合物的总重量,该化合物含有约29%到约30%的甲氧基团和约7%到约12%的羟丙基团。HPMC2910的商品化产品由DowChemical Company提供,其商品名METHOCELE。METHOCEL E 5是适用于本发明的HPMC2910的一个级别,在20℃,2%的水溶液中用Ubbelohde粘度计确定其粘度约4到6cps(4到6豪帕斯卡秒)。类似地,METHOCEL E 6适用于本发明的HPMC2910的另一个级别,在20℃,2%的水溶液中用Ubbelohde粘度计确定其粘度约5到7cps(5到7豪帕斯卡秒)。METHOCEL E 15适用于本发明的HPMC2910的另一个级别,在20℃,2%的水溶液中用Ubbelohde粘度计确定其粘度约15000 cps(15豪帕斯卡秒)。本文中使用的“置换度”指附在无水葡萄糖环上的置换基团的平均数目,而“羟丙基摩尔置换度”指每摩尔无水葡萄糖羟丙基的摩尔数。
本文中使用的“改性淀粉”包括为改进稳定性而交联、化学改性的淀粉,或为改进溶解特性而物理改性的淀粉。本文中使用的“预胶凝化淀粉”或“预配制淀粉”指已经预先润湿,然后干燥以增加冷水溶解度的改性淀粉。合适的改性淀粉可以由许多供应商商业化提供,例如,A.E.Staley Manufacturing Company,和National Starch & Chemical Company。一种合适的改性淀粉包括预胶凝化的蜡状玉米衍生淀粉,该淀粉由National Starch & Chemical Company提供的商品名PURITY GUM和FILMSET和它的衍生物、共聚物和混合物。这种蜡状玉米淀粉通常包含,基于该淀粉总重量约0%到约18%的直链淀粉和约100%到约82%的支链淀粉。
合适的木薯糊精包括由National Starch & Chemical Company提供的商品名CRYSTAL GUM或K-4484,和该物质的衍生物如衍生自木薯的改性食物淀粉,该淀粉由National Starch & Chemical以商品名PURITY GUM 40提供,以及该它物的共聚物和混合物。
本领域中已知的任何增稠剂可适用于流通物质。增稠剂的例子包括但不限于水胶体(本文中也指胶凝聚合物)例如藻酸盐、琼脂、瓜尔胶、剌槐豆、角叉菜胶、他拉胶、阿拉伯树胶、黄芪胶、果胶、黄原胶、吉兰糖、麦芽糊精、半乳糖甘露聚糖、pusstulan、昆布多糖、硬葡聚糖、阿拉伯树胶、菊粉、果胶、whelan、rhamsan、zooglan、methylan、壳多糖、环糊精、脱乙酰壳多糖,及它们的衍生物和混合物。其它合适的增稠剂包括可结晶碳水化合物等,和它们的衍生物和组合物。合适的可结晶碳水化合物包括单糖和寡糖。单糖中优选己醛糖如阿洛糖、阿卓糖、葡萄糖、甘露糖、古洛糖、艾杜糖、半乳糖、塔罗糖的D和L异构体,和己酮糖如果糖和山梨糖的D和L异构体以及它们的氢化类似物:如山梨糖醇和甘露糖醇。寡糖中优选1,2-二糖蔗糖和海藻糖,1,4-二糖麦芽糖、乳糖、纤维二糖、1,6-二糖龙胆二糖、蜜二糖、三糖棉子糖、以及蔗糖的异构形式称为异麦芽糖和它的氢化类似物异麦芽糖。优选还原性二糖(如麦芽糖和乳糖)的其它氢化形式,例如麦芽糖醇(maltitol)和乳梨醇(lactitil)。此外,优选戊醛糖的氢化形式:例如,D和L核糖、阿拉伯糖、木糖、和丁醛糖的氢化形式:例如,D和L赤藓糖,且分别以木糖醇和赤藓醇作为例子。
合适的黄原胶包括由C.P.Kelco Company以商品名KELTROL 1000,XANTROL180,或K9B310提供的物质。
合适的热塑性物质在加热时可模塑和成形,包括水溶性聚合物和不溶于水的聚合物,这些聚合物通常是线性的,不是交联的,没有强氢与邻近的聚合物链连结。合适的热塑性物质的例子包括:化学改良的纤维素衍生物如羟丙基纤维素(HPC)、羟丙甲基纤维素(HPMC)、甲基纤维素(MC)、醋酸纤维素(CA)、乙基纤维素(EC)、醋酸丁酸纤维素(CAB)、丙酸纤维素;乙烯聚合物如聚乙烯醇(PVA)和聚乙烯吡咯烷酮(PVP);热塑性淀粉、天然或化学改良蛋白质如明胶、大豆蛋白质分离物、乳清蛋白质、肌原纤维蛋白质,和来自乳的酪蛋白;和它们的衍生物和组合物。
制药领域中已知的任何增塑剂可适用于本发明,可以包括但不限于聚乙二醇;甘油;山梨糖醇;柠檬酸三乙酯;柠檬酸三丁酯;癸二酸二丁酯;植物油如蓖麻油;表面活性剂如聚山梨醇酯,十二烷基硫酸钠,和二辛基磺基琥珀酸钠;丙二醇;甘油单醋酸盐;甘油二醋酸盐;甘油三醋酸盐;天然胶和它们的混合物。在含有纤维素醚薄膜形成剂的溶液中,任选的增塑剂可以基于该溶液的总重量的约0%到约40%的量存在。
流动物质可任选包括辅剂或赋形剂,可包含流动物质重量的约20%。合适的辅剂或赋形剂例子包括防粘剂、致湿剂、表面活性剂、消泡沫剂、着色剂、食用香料、甜味剂、遮光剂等等。在一个较佳实施例中,流动物质包含少于5%致湿剂,或者可选择地大体上不含致湿剂,如甘油、山梨糖醇、麦芽糖醇、木糖醇或丙二醇。致湿剂常常被包括在用于涂糖衣加工的预形成薄膜中,如美国专利5,146,730和5,459,730所公开的,以保证在加工过程中薄膜有足够的柔性或可塑性和粘合性。致湿剂的作用是结合水分和在薄膜中保留水分。用于涂糖衣加工的预形成薄膜通常包括多至45%的水。不利的是,致湿剂的存在会延长干燥过程,也会对制成的剂型的稳定性有不利影响。
在本发明的一个较佳实施例中,剂型的镶嵌部分包含至少约80%优选约90%的材料选自薄膜形成剂、胶凝聚合物(水胶体)、热塑性物质、低熔点疏水物质、非结晶糖和它们的混合物。镶嵌部分可用注射模塑形成,有利于最低程度减少或排除直接压制需要的充填剂-粘合剂如微晶纤维素、喷雾干燥乳糖、矿物盐如磷酸钙、结晶糖如蔗糖、糊精等等。不利的是,这些物质会降低该镶嵌部分的透明性和稳定性。本发明的镶嵌部分包含少于约10%,如少于约1%,或少于约0.1%的直接压制充填剂-粘合剂较佳。所以用于本发明的镶嵌部分是对压制包衣的壳的改进,压制包衣的壳通常包含至少约30%的直接压制充填剂-粘合剂。见举例WO 00/18477。
镶嵌部分可以通过模塑制备,如上文所述。
在本发明的一个实施方案中,镶嵌部分包含改进释放组合物如美国专利申请系列号 00000000000(WO/ 0000000000)[MCP320],本文引入作为参考。
在本发明的另一个实施方案中,镶嵌部分包含任何改进释放组合物如美国专利申请系列号 00000000000000000000000000(WO/ 0000000000或WO/ 0000000000)[MCP322和323],本文引入作为参考。
在一个较佳实施方案中,镶嵌部分大体上不含有直径0.5到5.0微米的小孔。本文中使用的“大体上不含”指该镶嵌部分的小孔在小孔直径范围为0.5到5.0微米时体积小于约0.02cc/g,小于约0.01cc/g较佳,小于约0.005cc/g更佳。在此小孔直径范围中,典型的压制物质的小孔体积大于约0.02cc/g。小孔的体积、小孔的直径和密度可用Quantachrome Instruments PoreMaster 60汞挤入孔率计和相关的计算机软件程序“Porowin”来测定。该测定步骤由QuantachromeInstruments PoreMaster操作手册记载。PoreMaster设备确定固体或粉剂的小孔体积和小孔直径,通过非湿性液体(汞)加压挤入,包括排空样品池(穿透计)中的样品,向池内注入汞使样品周围环绕汞,向样品池提供压力,用:(I)压缩空气(最高至50psi);和(ii)水压(油压)压力发生器(最高至60000psi)。在提供的压力下,通过汞从样品外面移入小孔中带来的容量变化来测量挤入体积。挤入发生时相应的小孔大小直径通过所谓的“Washburn等式”直接计算:d=-(4γ(cosθ))/P,其中γ是液体汞的表面张力,θ是汞与样品表面的接触角度,P是提供的压力。
用于测量小孔体积的设备:
1.Quantachrome Instruments PoreMaster 60
2.能称0.0001g的分析天平
3.干燥器
用于测量的试剂:
1.高纯度氮
2.三重蒸馏的汞
3.高压液体(Dila AX,由Shell Chemical Co.提供)
4.液氮(用于汞蒸汽冷阱)
5.用于清洗样本池的异丙醇或甲醇
6.用于池清洗的液体洗涤剂
步骤:
样品在分析前被密封包装或安放在干燥器中。接通真空泵,汞蒸汽冷阱注入液氮,提供的压缩气体调节在55psi,开启设备,预热时间至少30分钟。空的穿透计池按照设备手册中的描述安装并记录其重量。该池被安置在低压站,在分析菜单上选择“只排空和充注”,并使用下列数值:
精细排空时间:1分钟
精细排空率:10
粗排空时间:5分钟
该池(已充注了汞)被移出和称重。然后在汞储存器中清空该池,每个样品的两小片被置于该池内,该池被重新装配。然后记录该池和样品的重量。该池被安置在低压站,从菜单上选择低压选项,并设定下列参数:
模式:低压
精细排空率:10
精细排空到:200μHg
粗排空时间:10分钟
充注压力:接触+0.1
最大压力:50
方向:挤入和挤出
重复:0
汞接触角度:140
汞表面张力;480
然后开始获取数据。关于压力与累计挤入体积关系的图显示在屏幕上。在低压分析结束后,该池从低压站移出并重新称重。汞以上的空间被充注液压油,该池被装配,并安装在高压腔中。使用下列参数:
模式;固定速率
发动机速度:5
起始压力:20
结束压力:60,000
方向:挤入和挤出
重复:0
油充注长度:5
汞接触角度:140
汞表面张力;480
开始获取数据,关于压力与挤入体积关系的图显示在屏幕上。在高压运行结束后,同一样品的低压和高压数据文件被合并。
在本发明的一个实施方案中,只有片心包含一种或多种活性成分。在本发明的另一个实施方案中,只有镶嵌部分包含一种或多种活性成分。而在本发明的另一个实施方案中,只有插入物包含一种或多种活性成分。而在本发明的另一个实施方案中,片心和镶嵌部分包含一种或多种活性成分。而在本发明的另一个实施方案中,一个或多个片心、镶嵌部分、或插入物包含一种或多种活性成分。
本发明的优点之一是镶嵌部分可以有复杂的几何形状或图案。例如,以前在现有技术中公开的插入物或镶嵌部分限于简单的形状,如圆形的横截面形状。使用现有技术,极难恰当地压制出复杂的标识图案,例如凹雕导致或需要在基底、片心表面中的不连线性或它在第一部分中必须镶嵌。但是,由于本发明的插入物或镶嵌部分是使用流动性物质获得的,或如果使用多个喷嘴可以用来充填任何形状或连续图案的任何抽空部分,乃至一种不连续的图案。
本发明的一个特殊优点是插入物或镶嵌部分在横截面上(至少是一部分)可比包含插入物或镶嵌部分的腔大。例如,在第二模塑部分镶嵌在剂型的第一部分的外表面中的一个或多个腔内的实施方案中,第二模塑镶嵌部分的至少一个横截面面积比第一部分的表面的腔的横截面面积大。相反,现有技术中插入物的横截面面积必须不大于容纳插入物的腔的开口。这也可用插入物或镶嵌部分的“锥度”来表示。本文中使用的术语“锥度”指腔的侧壁和与第一部分的面垂直线限定的角度,例如Rosato等,《 注射成型手册》(Injection Molding Handbook)第601-04页,(第2版1995),本文引入作为参考。本文用图3A和3b说明。在图3A中,显示现有技术插入物300插入片心304的腔302中。锥度θ由垂直线306和侧壁307确定,θ必须有零或正值。但是,本发明中θ可以有小于零的值。
相反,在图3B中显示的本发明的插入物或镶嵌部分500插入片心504的腔502中。锥度θ由腔502和片心504的交叉点射出的垂直线506和插入物500的侧面508确定,如图所示小于0°。这是由于插入物500的第一末端509比腔502宽。但是,由于插入物是由流动性物质组成,插入物500可充填腔502。所以,插入物500可被“锁”或交锁在腔502内。
本发明将通过下列实施例进一步阐明,这些实施例并不意味着以任何形式限制本发明。
实施例1
本发明的剂型是使用包含压制模制和两个热循环成型模制,通过第一和第二传递装置连接成系列的设备进行连续加工制备的,如待批的美国专利申请系列号09/966,939的第14-16页所述,本文引入作为参考。该剂型包含压制的片心,片心上有壳,壳包含形成镶嵌图案的第一壳部分和第二壳部分。
片心由下列成分的混合物制备:对乙酰氨基酚USP(590mg/片)、合成蜡X-2068T20(53mg/片)、羟基乙酸淀粉钠(EXPLOTAB)(13.9mg/片)、二氧化硅(0.6mg/片)、硬脂酸镁NF(2.4mg/片)。这些成分被进行干混合,就是在压制模件上被压制成片心,按照待批的美国专利申请序列号09/966,509的第16到27页(本文引入作为参考)所述使用7/16英寸特深凹片剂加工。该压制模件是一个双排,旋转设备,包含充填区、插入区、压制区、射出区和清除区,如美国专利申请序列号09/966,509的图6所示。该压制模件的模具用真空辅助充填,通过位于每个模具的模壁口的网眼筛过滤器。制成的片剂的平均重量是660mg,厚度是0.306英寸,和硬度是3.2kp。
片心通过如待批的美国专利申请序列号09/966,414的第51到57页所述的第一传递装置,被转移至如待批的美国专利申请序列号09/966,497的第27到51页所述的第一热循环成型模件,本文引作为参考。第一和第二传递装置的结构如待批的美国专利申请系列号09/966,414中图3的300所示,分别将片心从压制模件转移到第一热循环成型模件和从第一热循环成型模件转移到第二热循环成型模件。传递装置包含许多以悬臂形式连接到带子312上的传递单元304,如待批的美国专利申请系列号09/966,414的图68和69所示。第一传递装置与相连接的压制模件和第一热循环成型模件同步旋转和运行。第二传递装置与相连接的第一热循环成型模件和第二热循环成型模件同步旋转和运行。传递单元304包含定位器330,该定位器用于放置围绕传递装置移动的片心。
片剂在第一热循环成型模件中被包含红色明胶的第一壳部分包被。如待批的美国专利申请序列号09/966,939的图28A所示的类型。热循环成型共同待定的模具单元204包含如图28C所示的上模具组合件214、可旋转中心模具组合件212和下模具组合件210。片心被转移至模具组合件,然后模具组合件关闭,片心上的镶嵌图案被模具组合件的内表面遮蔽,留下镜图象镶嵌图案暴露在片心的表面。  第一壳流动物质,如下文所述,在贮主206加热到流动状态,被注入到关闭的模具组合件形成的模腔中。由于遮蔽,流动物质只能用于片心的暴露部分。然后第一壳流动物质的温度被降低,硬化。模具组合件打开,且被部分包被的片心弹出到第二传递装置,该装置把片心传递到第二热循环成型模件。
包含红色明胶包衣的第一壳部分,由下列成分制备:净化水,Opatint红DD-1761,Opatint黄DD-2125,275 Bloom猪皮明胶和250 Bloom骨明胶(150g)一起作为干明胶颗粒的混合物。明胶浆由这些成分形成并加热到55℃以熔化和溶解明胶。明胶溶液被保持在55℃大约3小时(在这个温度的保持时间通常可在约2小时到约16小时范围)。然后该溶液被混合至均匀(约5到15分钟)。当明胶溶液在第一热循环成型模件中使用时,明胶溶液被保持在55℃连续混合。
第二热循环成型模件也是如待批的美国专利申请序列号09/966,497的图26A所示的类型。第二壳部分(由净化水(450g),Opatint黄DD-2125(6.2g),275 Bloom猪皮明胶(150g)和250 Bloom骨明胶(150g)以与第一壳部分相同的方法制备)可应用到片心。第二热循环成型模件的上和中模具组合件配合,使前述的片心的暴露部分(现包被了第一壳部分)被遮蔽。这使先前遮蔽的尚未包被的片心部分暴露出来。第二流动物质在贮主206加热到流动状态,被注入到配合的上和中模具组合件中。然后第二流动物质的温度被降低,硬化,使第二流动物质形成镶嵌图案。模具组合件打开,弹出完成的剂型。
虽然本发明通过特定的实施方案作了阐明,本领域的熟练技术人员应当明白进行的各种改变和改进无疑属于本发明的范围内。

Claims (42)

1.一种剂型,所述剂型包含至少一种活性成分,第一部分包含一个外表面和一个或多个定义为至少一个有凹口的内表面的腔,和镶嵌在第一部分的腔内和有外表面的第二模塑部分,其中,第一和第二部分在界面上接触,第二部分包括凝固的热塑性物质,第二部分大体上正形地在凹口上。
2.权利要求1所述的剂型,其特征在于,第二模塑部分大体上没有直径0.5到5.0微米的孔。
3.权利要求1所述的剂型,其特征在于,第一和第二部分在界面上紧密接触。
4.权利要求1所述的剂型,其特征在于,第一部分是压制的片剂。
5.权利要求1所述的剂型,其特征在于,第一部分是模塑的片剂。
6.权利要求1所述的剂型,其特征在于,第一部分包含凹雕,第二部分在凹雕中。
7.权利要求1所述的剂型,其特征在于,第二部分的外表面与第一部分的外表面齐平。
8.权利要求1所述的剂型,其特征在于,第二部分的外表面高于第一部分的外表面。
9.权利要求1所述的剂型,其特征在于,第一部分基本上由单一均质层组成。
10.权利要求1所述的剂型,其特征在于,第二模塑部分包含至少一种活性成分。
11.权利要求1所述的剂型,其特征在于,第一部分有第一种颜色,镶嵌的第二部分有第二种颜色。
12.权利要求1所述的剂型,其特征在于,第一部分包含第一活性成分和镶嵌的第二部分包含与第一活性成分相同或不同的第二活性成分。
13.权利要求1所述的剂型,其特征在于,第一和第二部分一起构成预先安排的式样。
14.权利要求1所述的剂型,其特征在于,第一部分包含微电子装置。
15.权利要求1所述的剂型,其特征在于,第一部分中的一个或多个腔的内表面的锥度值小于零。
16.权利要求1所述的剂型,其特征在于,界面与内表面大体上同等延伸。
17.权利要求1所述的剂型,其特征在于,第一部分是不连续的,第二部分是连续的。
18.一种剂型,所述剂型包含至少一种活性成分,片心有外表面,壳至少在片心外表面的一部分上,其中,壳包含第一壳部分和第二模塑壳部分,第二模塑壳部分镶嵌在第一模塑壳部分中,第一和第二壳部分在界面上接触。
19.权利要求18所述的剂型,其特征在于,壳有外表面,第二模塑壳部分从片心的外表面延伸到壳的外表面。
20.权利要求18所述的剂型,其特征在于,第一和第二壳部分都是不连续的。
21.权利要求18所述的剂型,其特征在于,第一壳部分有第一颜色,第二壳部分有第二颜色。
22.权利要求18所述的剂型,其特征在于,片心包含压缩的粉剂。
23.权利要求18所述的剂型,其特征在于,片心包含插入物。
24.权利要求23所述的剂型,其特征在于,插入物包含一种活性成分。
25.权利要求24所述的剂型,其特征在于,一个或多个片心、镶嵌部分或插入物包含一种活性成分。
26.权利要求18所述的剂型,其特征在于,片心包含微电子装置。
27.权利要求23所述的剂型,其特征在于,插入物包含微电子装置。
28.权利要求18所述的剂型,其特征在于,第一壳部分、第二壳部分,或两者有带织纹的外表面。
29.权利要求18所述的剂型,其特征在于,壳的外表面包含预先安排的图案。
30.权利要求18所述的剂型,其特征在于,壳包含在其中的一个或多个开口。
31.权利要求18所述的剂型,其特征在于,壳的外表面大体上光滑。
32.权利要求18所述的剂型,其特征在于,壳含有凹口、字母、符号或图案。
33.权利要求18所述的剂型,其特征在于,第一壳部分含有凹口、字母、符号或图案。
34.权利要求18所述的剂型,其特征在于,第二壳部分含有凹口、字母、符号或图案。
35.权利要求18所述的剂型,其特征在于,第一壳部分、第二壳部分,或两者含有以字母、符号或图案形式的突出部分。
36.权利要求18所述的剂型,其特征在于,镶嵌部分大体上没有直径0.5到5.0微米的孔。
37.权利要求18所述的剂型,其特征在于,第一壳部分在界面的锥度值小于零。
38.一种剂型,所述剂型包含至少一种活性成分、片心、和有不连续的第一模塑壳部分和连续的第二模塑壳部分的壳,第一壳部分的不连续是由于第二模塑壳部分的存在,第一和第二壳部分在成分上不同。
39.权利要求18所述的剂型,其特征在于,第一和第二壳部分包括凝固的热塑性物质。
40.权利要求18所述的剂型,其特征在于,第一和第二壳部分的外表面是共面的。
41.权利要求1所述的剂型,其特征在于,腔确定为许多用于容纳镶嵌部分的侧壁,该侧壁有小于零的锥度值。
42.权利要求1所述的剂型,其特征在于,第二模塑镶嵌部分的至少一个横截面的面积比第一部分的表面上腔的横截面面积大。
CNB028234308A 2001-09-28 2002-09-28 有镶嵌部分的组合剂型 Expired - Fee Related CN100408029C (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US09/966,450 US6982094B2 (en) 2001-09-28 2001-09-28 Systems, methods and apparatuses for manufacturing dosage forms
US09/967,414 2001-09-28
US09/966,509 US6767200B2 (en) 2001-09-28 2001-09-28 Systems, methods and apparatuses for manufacturing dosage forms
US09/966,497 US7122143B2 (en) 2001-09-28 2001-09-28 Methods for manufacturing dosage forms
US09/966,509 2001-09-28
US09/966,450 2001-09-28
US09/967,414 US6742646B2 (en) 2001-09-28 2001-09-28 Systems, methods and apparatuses for manufacturing dosage forms
US09/966,939 US6837696B2 (en) 2001-09-28 2001-09-28 Apparatus for manufacturing dosage forms
US09/966,939 2001-09-28
US09/966,497 2001-09-28

Publications (2)

Publication Number Publication Date
CN1607945A true CN1607945A (zh) 2005-04-20
CN100408029C CN100408029C (zh) 2008-08-06

Family

ID=27542311

Family Applications (10)

Application Number Title Priority Date Filing Date
CNA028236416A Pending CN1596104A (zh) 2001-09-28 2002-09-28 改进的释放剂型
CNA028233549A Pending CN1592612A (zh) 2001-09-28 2002-09-28 有内核和外壳的剂型
CNA028236505A Pending CN1596101A (zh) 2001-09-28 2002-09-28 含有糖果组分的剂型
CNA028233476A Pending CN1592610A (zh) 2001-09-28 2002-09-28 改良的释放剂型
CNB028233727A Expired - Fee Related CN100364515C (zh) 2001-09-28 2002-09-28 具有不同形状内核和外壳的剂型
CNA028233441A Pending CN1592611A (zh) 2001-09-28 2002-09-28 改良释放的剂型
CNB028234308A Expired - Fee Related CN100408029C (zh) 2001-09-28 2002-09-28 有镶嵌部分的组合剂型
CNA028236386A Pending CN1596100A (zh) 2001-09-28 2002-09-28 可食用组合物及含可食用外壳的制剂
CNA028233611A Pending CN1638740A (zh) 2001-09-28 2002-09-28 释出得到修饰的剂型
CNA028235401A Pending CN1596102A (zh) 2001-09-28 2002-09-28 调节释放剂型

Family Applications Before (6)

Application Number Title Priority Date Filing Date
CNA028236416A Pending CN1596104A (zh) 2001-09-28 2002-09-28 改进的释放剂型
CNA028233549A Pending CN1592612A (zh) 2001-09-28 2002-09-28 有内核和外壳的剂型
CNA028236505A Pending CN1596101A (zh) 2001-09-28 2002-09-28 含有糖果组分的剂型
CNA028233476A Pending CN1592610A (zh) 2001-09-28 2002-09-28 改良的释放剂型
CNB028233727A Expired - Fee Related CN100364515C (zh) 2001-09-28 2002-09-28 具有不同形状内核和外壳的剂型
CNA028233441A Pending CN1592611A (zh) 2001-09-28 2002-09-28 改良释放的剂型

Family Applications After (3)

Application Number Title Priority Date Filing Date
CNA028236386A Pending CN1596100A (zh) 2001-09-28 2002-09-28 可食用组合物及含可食用外壳的制剂
CNA028233611A Pending CN1638740A (zh) 2001-09-28 2002-09-28 释出得到修饰的剂型
CNA028235401A Pending CN1596102A (zh) 2001-09-28 2002-09-28 调节释放剂型

Country Status (20)

Country Link
US (15) US20040213848A1 (zh)
EP (12) EP1438028A1 (zh)
JP (11) JP2005508329A (zh)
KR (11) KR20040037206A (zh)
CN (10) CN1596104A (zh)
AT (4) ATE376826T1 (zh)
AU (1) AU2002330164A1 (zh)
BR (11) BR0212951A (zh)
CA (12) CA2461653A1 (zh)
CO (1) CO5570655A2 (zh)
DE (4) DE60237294D1 (zh)
ES (3) ES2295427T3 (zh)
HK (1) HK1072902A1 (zh)
HU (1) HUP0401686A3 (zh)
MX (12) MXPA04002977A (zh)
NO (4) NO20032364L (zh)
NZ (3) NZ532568A (zh)
PL (1) PL369134A1 (zh)
PT (1) PT1429738E (zh)
WO (12) WO2003026612A2 (zh)

Families Citing this family (314)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
ES2221370T3 (es) * 1998-04-03 2004-12-16 Egalet A/S Composicion de liberacion controlada.
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP1429744A1 (en) * 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
EP1429739A1 (en) * 2001-09-21 2004-06-23 Egalet A/S Polymer release system
NZ532568A (en) 2001-09-28 2005-07-29 Mcneil Ppc Inc Modified release dosage forms
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
JP5069395B2 (ja) * 2002-02-21 2012-11-07 ヴァレアント インターナショナル (バルバドス) エスアールエル トラマドールの少なくとも1つの形の放出が改良された医薬組成物
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7169450B2 (en) 2002-05-15 2007-01-30 Mcneil-Ppc, Inc. Enrobed core
US20060083791A1 (en) * 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1581197A1 (en) * 2002-12-11 2005-10-05 Ranbaxy Laboratories, Limited Coating composition for taste masking coating and methods for their application and use
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP2186510B1 (en) * 2003-03-26 2013-07-10 Egalet Ltd. Matrix compositions for controlled delivery of drug substances
DE602004031096D1 (de) 2003-03-26 2011-03-03 Egalet As Morphin-system mit kontrollierter freisetzung
EP1615626B1 (en) * 2003-04-24 2009-10-14 Jagotec Ag Tablet with coloured core
WO2004093843A1 (en) 2003-04-24 2004-11-04 Jagotec Ag Delayed release tablet with defined core geometry
JP2007502331A (ja) * 2003-05-29 2007-02-08 グリュコン テクノロジーズ グループ エルエルシー (−)−ヒドロキシクエン酸を安定して制御送達するための方法および組成物
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528636A (ja) 2003-07-24 2006-12-21 スミスクライン・ビーチャム・コーポレイション 経口溶解性フィルム
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1653924A4 (en) * 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2005075826A (ja) * 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh 多孔質シリカ担体を含有する徐放性製剤
GB0320854D0 (en) * 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
WO2005046363A2 (en) 2003-11-07 2005-05-26 U.S. Smokeless Tobacco Company Tobacco compositions
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
EP1731151A4 (en) * 2004-03-10 2013-05-01 Taisho Pharmaceutical Co Ltd SOLID PHARMACEUTICAL PREPARATION WITH A HEAVY WATER-SOLUBLE MEDICAMENT
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
EP2258349B1 (en) * 2004-05-11 2014-07-16 Egalet Ltd. Swellable dosage form comprising gellan gum
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060002986A1 (en) * 2004-06-09 2006-01-05 Smithkline Beecham Corporation Pharmaceutical product
TWI356036B (en) * 2004-06-09 2012-01-11 Smithkline Beecham Corp Apparatus and method for pharmaceutical production
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US8609198B2 (en) * 2004-07-21 2013-12-17 Hewlett-Packard Development Company, L.P. Pharmaceutical dose form with a patterned coating and method of making the same
WO2006012634A1 (en) * 2004-07-26 2006-02-02 Teva Pharmaceutical Indudstries, Ltd. Dosage forms with an enterically coated core tablet
US7621734B2 (en) * 2004-07-28 2009-11-24 Mars, Incorporated Apparatus and process for preparing confectionery having an inclusion therein using forming rolls and a forming pin
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
EP1639899A1 (en) * 2004-08-23 2006-03-29 Friesland Brands B.V. Powdered, cold-water soluble/dispersible, foamable composition
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1944005A3 (en) * 2004-09-24 2008-07-23 BioProgress Technology Limited Additional improvements in powder compaction and enrobing
AU2005286288A1 (en) * 2004-09-24 2006-03-30 Bioprogress Technology Limited Additional improvements in powder compaction and enrobing
EP1799453B1 (en) * 2004-09-30 2012-09-05 MonoSolRX, LLC Multi-layer films having uniform content
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006044657A2 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
US20060093560A1 (en) * 2004-10-29 2006-05-04 Jen-Chi Chen Immediate release film coating
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
DK1836665T3 (da) 2004-11-19 2013-04-15 Glaxosmithkline Llc Fremgangsmåde til specialtilpasset afgivelse af medikamentkombinationsprodukter med variabel dosis til individualisering af terapier
US7404708B2 (en) * 2004-12-07 2008-07-29 Mcneil-Ppc, Inc. System and process for providing at least one opening in dosage forms
US7530804B2 (en) * 2004-12-07 2009-05-12 Mcneil-Ppc, Inc. System and process for providing at least one opening in dosage forms
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
WO2006070930A1 (en) 2004-12-27 2006-07-06 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
WO2006072577A1 (en) * 2005-01-07 2006-07-13 Sandoz Ag Process for preparing granulates comprising amoxicillin
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2006099618A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
US9713592B2 (en) * 2005-04-06 2017-07-25 Mallinckrodt Llc Matrix-based pulse release pharmaceutical formulation
WO2006110807A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
AU2006241771B2 (en) * 2005-04-28 2010-09-09 Eisai R & D Management Co., Ltd. Composition containing anti-dementia drug
CA2608144C (en) 2005-04-28 2012-11-13 Proteus Biomedical, Inc. Pharma-informatics system
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
DE602006020133D1 (de) * 2005-05-18 2011-03-31 Goemar Lab Sa Laminarin-enthaltende lebensmittel
CN101188999B (zh) * 2005-06-03 2012-07-18 尹格莱特股份有限公司 用于递送分散在分散介质中的活性物质的药物传递系统
AU2006261788B2 (en) * 2005-06-27 2012-05-31 Valeant International Bermuda Modified-release formulations of a bupropion salt
US20070009573A1 (en) * 2005-07-07 2007-01-11 L N K International Method of forming immediate release dosage form
DE102005034043B4 (de) * 2005-07-18 2019-12-12 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
JP2009504779A (ja) * 2005-08-17 2009-02-05 アルテアナノ インコーポレイテッド 家畜における慢性腎不全及びその他の病気の治療:組成物及び方法
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
KR20080075113A (ko) * 2005-10-14 2008-08-14 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온을 함유하는 안정한 약학적제형
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007086846A1 (en) * 2006-01-24 2007-08-02 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2007224012A (ja) * 2006-01-30 2007-09-06 Fujifilm Corp 酵素架橋したタンパク質ナノ粒子
US20070184111A1 (en) * 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
US20070190131A1 (en) * 2006-02-10 2007-08-16 Perry Ronald L Press-fit rapid release medicament and method and apparatus of manufacturing
US20070224258A1 (en) * 2006-03-22 2007-09-27 Bunick Frank J Dosage forms having a randomized coating
CA2647536C (en) * 2006-03-28 2015-01-27 Mcneil-Ppc, Inc. Non-homogenous dosage form coatings
CN101453996B (zh) * 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
CN101453993A (zh) 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070293587A1 (en) * 2006-05-23 2007-12-20 Haley Jeffrey T Combating sinus, throat, and blood infections with xylitol delivered in the mouth
CN102582106B (zh) * 2006-05-23 2015-12-16 奥拉黑尔斯公司 具有阿拉伯树胶粘合剂的双层口用粘附性片剂
BRPI0712285A2 (pt) * 2006-06-19 2012-01-10 Accu Break Technologies Inc forma de dosagem e método de utilização de uma forma de dosagem
SI2049123T2 (sl) 2006-08-03 2016-10-28 Horizon Pharma Ag Zdravljenje revmatoznih bolezni z zadržanim sproščanjem glukokortikoida
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8399230B2 (en) 2006-10-12 2013-03-19 Kemin Industries, Inc. Heat-stable enzyme compositions
EP1916006A1 (en) * 2006-10-19 2008-04-30 Albert Schömig Implant coated with a wax or a resin
EP2089013B1 (en) * 2006-10-20 2017-09-27 Johnson & Johnson Consumer Inc. Combination of acetaminophen with ibuprofen for the treament of pain
BRPI0718428A2 (pt) * 2006-10-25 2013-11-12 Mcneil Ppc Inc Composição de ibuprofeno
WO2008086804A2 (en) * 2007-01-16 2008-07-24 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US7767248B2 (en) 2007-02-02 2010-08-03 Overly Iii Harry J Soft chew confectionary with high fiber and sugar content and method for making same
GB0702974D0 (en) * 2007-02-15 2007-03-28 Jagotec Ag Method and apparatus for producing a tablet
JP5224790B2 (ja) * 2007-03-02 2013-07-03 株式会社明治 固形食品およびその製造方法
US8895061B2 (en) * 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US20080292692A1 (en) * 2007-05-21 2008-11-27 Shira Pilch Impermeable Capsules
US20080300322A1 (en) * 2007-06-01 2008-12-04 Atlantic Pharmaceuticals, Inc. Delivery vehicles containing rosin resins
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
AR066862A1 (es) * 2007-06-11 2009-09-16 Procter & Gamble Particula de suministro que contiene agentes beneficos
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20080317677A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
JP5965583B2 (ja) * 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー 乱用抵抗性医薬組成物、その使用方法および作製方法
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
EP2197448A4 (en) * 2007-09-12 2010-11-17 Elan Pharma Int Ltd dosing schedule
AR066166A1 (es) * 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
FR2921835B1 (fr) * 2007-10-05 2012-05-04 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition d'enrobage comprenant du polydextrose, procede pour sa preparation et utilisation pour enrober les formes solides ingerables
US8303573B2 (en) 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
JP4879351B2 (ja) 2007-10-19 2012-02-22 大塚製薬株式会社 医薬固形製剤
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8333754B2 (en) * 2007-10-31 2012-12-18 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8109920B2 (en) * 2007-10-31 2012-02-07 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
MX2010004897A (es) * 2007-10-31 2010-05-19 Mcneil Ppc Inc Forma de dosificacion oralmente desintegrada.
US20090137866A1 (en) * 2007-11-28 2009-05-28 Searete Llc, A Limited Liability Corporation Of The State Delaware Medical or veterinary digestive tract utilization systems and methods
CA2956278C (en) 2008-01-04 2022-03-01 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine and applications thereof
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2262484B1 (en) 2008-03-11 2013-01-23 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
WO2009135680A1 (en) 2008-05-09 2009-11-12 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
WO2009140351A2 (en) * 2008-05-14 2009-11-19 Cadbury Adams Usa Llc Confectionery with enzymatically manipulated texture
WO2009146537A1 (en) * 2008-06-02 2009-12-10 Pharmascience Inc. Multilayer control-release drug delivery system
KR200452140Y1 (ko) * 2008-06-20 2011-02-08 주식회사 부성시스템 비닐하우스의 부직포개폐기용 제어장치
JP5681626B2 (ja) 2008-07-14 2015-03-11 ポリーペイド リミテッドPolypid Ltd. 徐放性薬剤キャリア組成物
KR200450450Y1 (ko) * 2008-07-16 2010-10-04 이봉석 포지션 리미트 스위치 케이스
JP2011530529A (ja) * 2008-08-07 2011-12-22 アバントール パフォーマンス マテリアルズ, インコーポレイテッド ゴムおよび糖アルコールを含む徐放性組成物
US8038424B2 (en) 2008-09-22 2011-10-18 Xerox Corporation System and method for manufacturing sold ink sticks with an injection molding process
FR2936952A1 (fr) * 2008-10-09 2010-04-16 Monique Bellec Administration par voie orale de medicaments et complements nutritionnels
IT1394597B1 (it) * 2008-11-05 2012-07-05 Politi Granulazione a secco in flusso di gas.
WO2010067478A1 (ja) * 2008-12-12 2010-06-17 株式会社ミツヤコーポレーション 食品およびその加工方法
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
US8603526B2 (en) 2009-02-06 2013-12-10 Egalet Ltd. Pharmaceutical compositions resistant to abuse
HUE049501T2 (hu) * 2009-02-13 2020-09-28 Romark Laboratories Lc Nitazoxanidot tartalmazó szabályozott felszabadulású gyógyszerkészítmény
EP3906845A1 (en) 2009-04-28 2021-11-10 Otsuka Pharmaceutical Co., Ltd. Highly reliable ingestible event markers
CN102421421A (zh) * 2009-05-12 2012-04-18 Bpsi控股有限责任公司 含有抗黏性剂细微颗粒的包衣和覆有该包衣的基体
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
US8992979B2 (en) 2009-07-14 2015-03-31 Polypid Ltd. Sustained-release drug carrier composition
CN102573806B (zh) 2009-07-22 2015-02-25 格吕伦塔尔有限公司 用于对氧化敏感的阿片类物质的抗破坏剂型
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
EP2457449A4 (en) * 2009-07-24 2014-01-01 Nihon Kraft Foods Ltd MULTIPLE CANDY AND MANUFACTURING METHOD THEREFOR
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US20120141584A1 (en) * 2009-08-26 2012-06-07 Aptapharma, Inc. Multilayer Minitablets
PL399450A1 (pl) * 2009-08-31 2013-01-21 Depomed, Inc Utrzymujace sie w zoladku kompozycje farmaceutyczne do natychmiastowego i przedluzonego uwalniania acetaminofenu
CN102575016B (zh) * 2009-09-01 2015-06-10 罗地亚管理公司 聚合物组合物
US9610224B2 (en) 2009-09-24 2017-04-04 Johnson & Johnson Consumer Inc. Manufacture of tablet in a die utilizing powder blend containing water-containing material
US20110318411A1 (en) 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
US8313768B2 (en) * 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
EP2316432A1 (de) * 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
UA109424C2 (uk) * 2009-12-02 2015-08-25 Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
CN102639122A (zh) * 2009-12-07 2012-08-15 麦克内尔-Ppc股份有限公司 调释剂型的部分浸渍包衣
BR112012014899A2 (pt) 2009-12-18 2017-03-14 Idenix Pharmaceuticals Inc composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
US10485770B2 (en) 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
JP5860409B2 (ja) 2010-01-19 2016-02-16 ポリピッド リミテッド 徐放性核酸マトリックス組成物
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
EP2544887A1 (en) * 2010-03-11 2013-01-16 Wockhardt Limited A device for the manufacture of a dosage form with a hole and method of manufacture
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
US8486013B2 (en) * 2010-03-18 2013-07-16 Biotronik Ag Balloon catheter having coating
US9743688B2 (en) 2010-03-26 2017-08-29 Philip Morris Usa Inc. Emulsion/colloid mediated flavor encapsulation and delivery with tobacco-derived lipids
KR20170121299A (ko) 2010-04-07 2017-11-01 프로테우스 디지털 헬스, 인코포레이티드 소형의 섭취가능한 장치
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
BR112012028629B8 (pt) 2010-05-12 2022-10-25 Spectrum Pharmaceuticals Inc Método de produzir um composto de carbonato de lantânio, e, composição farmacêutica
US20110280936A1 (en) * 2010-05-17 2011-11-17 Aptapharma, Inc. Self Breaking Tablets
WO2011161666A2 (en) * 2010-06-21 2011-12-29 White Innovation Ltd. Enclosed liquid capsules
CA2809993A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
JP5872558B2 (ja) 2010-09-01 2016-03-01 アムビト ビオスシエンセス コルポラチオン ピラゾリルアミノキナゾリンの臭化水素酸塩
EP2611425B1 (en) 2010-09-02 2014-07-02 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
US10821085B2 (en) * 2010-12-07 2020-11-03 Kimberly-Clark Worldwide, Inc. Wipe coated with a botanical composition having antimicrobial properties
AU2011342893A1 (en) 2010-12-13 2013-05-02 Purdue Pharma L.P. Controlled release dosage forms
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
EP2670396A1 (en) 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
CN105853445A (zh) 2011-06-06 2016-08-17 橡冠科学研究院 采用芯吸释放窗口的药物递送装置
USD723766S1 (en) 2011-06-30 2015-03-10 Intercontinental Great Brands Llc Confectionary article
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2013017242A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
WO2013055360A1 (en) 2011-10-14 2013-04-18 Hill's Pet Nutrition, Inc. Process for preparing a food composition
KR101384055B1 (ko) * 2012-02-02 2014-04-14 한국원자력연구원 버스트형 지연 방출 제어 조성물 및 이의 제조방법
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
CN104334545A (zh) 2012-03-16 2015-02-04 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US20130261372A1 (en) * 2012-03-30 2013-10-03 Elwha LLC, a limited liability company of the State of Delaware Device, System, and Method for Delivery of Sugar Glass Stabilized Compositions
TR201815502T4 (tr) 2012-04-18 2018-11-21 Gruenenthal Gmbh Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu.
WO2013165961A1 (en) * 2012-04-30 2013-11-07 Bettinger, Christopher J. A water-activated, ingestible battery
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9445971B2 (en) * 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
TW201400146A (zh) * 2012-06-05 2014-01-01 Takeda Pharmaceutical 有核錠
CN104684548A (zh) 2012-07-06 2015-06-03 埃格勒特有限责任公司 防止滥用的控释药物组合物
CN102824640A (zh) * 2012-08-06 2012-12-19 济南圣泉唐和唐生物科技有限公司 一种胶囊壳及其制备方法
US20140193543A1 (en) * 2013-01-09 2014-07-10 Alexander Vigneri Decorative hollow chocolate confection with improved writability
TWI659994B (zh) 2013-01-29 2019-05-21 美商普羅托斯數位健康公司 高度可膨脹之聚合型薄膜及包含彼之組成物
DE102013004263A1 (de) 2013-03-13 2014-09-18 Martin Lipsdorf Schnell lösliche orale Darreichungsform und Methode zur Herstellung derselben
WO2014144738A1 (en) 2013-03-15 2014-09-18 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
CN105163722A (zh) 2013-03-15 2015-12-16 英秋博实验室有限公司 多阶段生物可降解药物递送平台
EP2976082A4 (en) 2013-03-15 2016-05-11 Inspirion Delivery Technologies Llc MISS-INFANT COMPOSITIONS AND METHODS OF USE
US9470489B2 (en) * 2013-05-14 2016-10-18 Kerry Thaddeus Bowden Airsoft marking round
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
EP3079659B1 (en) 2013-12-11 2020-10-28 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
AU2014364930B2 (en) * 2013-12-16 2017-06-15 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations
JP6296371B2 (ja) * 2013-12-23 2018-03-20 ウェン、シャオガンWEN, Xiaoguang 二層錠剤の調製方法
JP6505721B2 (ja) 2014-01-10 2019-04-24 ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッド 高周波及び損失性被覆粒子を使用した錠剤の製造プロセス
US9375033B2 (en) 2014-02-14 2016-06-28 R.J. Reynolds Tobacco Company Tobacco-containing gel composition
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
DK3119762T3 (da) 2014-03-20 2021-08-30 Capella Therapeutics Inc Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
WO2015143161A1 (en) 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
KR102034202B1 (ko) 2014-12-23 2019-10-18 에스엠에이 세라퓨틱스 아이엔씨. 3,5-디아미노피라졸 키나제 억제제
WO2016116619A1 (de) * 2015-01-22 2016-07-28 Pfeifer & Langen GmbH & Co. KG Cellobiosehaltige zuckermasse
US10174275B2 (en) * 2015-01-30 2019-01-08 Follmann Gmbh & Co. Kg Thermally opening stable core/shell microcapsules
USD765828S1 (en) 2015-02-19 2016-09-06 Crossford International, Llc Chemical tablet
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US20190022013A1 (en) 2015-12-19 2019-01-24 First Time Us Generics Llc Soft-chew tablet pharmaceutical formulations
CN108712900A (zh) 2015-12-19 2018-10-26 第时间美国泛型药物有限公司 软咀嚼片剂药物制剂
JP2017158534A (ja) * 2016-03-07 2017-09-14 焼津水産化学工業株式会社 チップ状食品の製造方法及びチップ状食品
US20190076365A1 (en) * 2016-03-15 2019-03-14 Astellas Pharma Inc. Tablet
MX2019000888A (es) 2016-07-22 2019-06-03 Proteus Digital Health Inc Percepcion y deteccion electromagnetica de marcadores de evento ingeribles.
RU2019109633A (ru) * 2016-09-09 2020-10-09 Мерк Патент Гмбх Способ изготовления твердой фармацевтической лекарственной формы
MX2019003039A (es) 2016-09-26 2019-07-08 Procter & Gamble Forma de dosificacion de alivio prolongado.
WO2018081337A1 (en) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
CN106945323B (zh) * 2017-03-14 2018-11-02 常熟市双月机械有限公司 一种高效率的金属粉末液压机
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US10604631B2 (en) * 2017-04-07 2020-03-31 The Procter & Gamble Company Water-soluble films
DE102017107845A1 (de) 2017-04-11 2018-10-11 Gelita Ag Gelatineprodukt mit einer Kernkomponente und Verfahren zu dessen Herstellung
US11192139B2 (en) 2017-06-22 2021-12-07 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited organic coating
CN110719968A (zh) 2017-06-22 2020-01-21 宝洁公司 包括水溶性层和气相沉积无机涂层的膜
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CA3090183C (en) * 2018-03-05 2021-06-01 Kashiv Biosciences, Llc Programmable pharmaceutical compositions for chrono drug release
EP3587467A1 (de) * 2018-06-25 2020-01-01 Rudolf GmbH Funktionelle mehrwandige kern-schale-partikel
US20210259275A1 (en) * 2018-06-28 2021-08-26 Mars, Incorporated Improved edible ink formulations including calcium carbonate
KR102151342B1 (ko) * 2019-03-18 2020-09-02 박문수 구강용 캡슐 및 이의 제조방법
CN110006918B (zh) * 2019-04-17 2021-04-30 湖北三环锻造有限公司 一种用于渗透探伤工艺的渗透探伤剂
CA3150979A1 (en) * 2019-09-12 2021-03-18 Nulixir Inc. Controlled release core-shell particles and suspensions including the same
IL299845A (en) 2020-07-15 2023-03-01 Schabar Res Associates Llc Oral unit dose compounds consisting of ibuprofen and famotidine for the treatment of acute pain and to reduce the severity and/or risk of heartburn
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Family Cites Families (439)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US231117A (en) * 1880-08-10 Folding boat
US231163A (en) * 1880-08-17 hamlin
US231129A (en) * 1880-08-10 wiesebrook
US231062A (en) * 1880-08-10 Felt hat
US3371136A (en) * 1968-02-27 United States Borax Chem Detergent tablet forming machine
US542614A (en) * 1895-07-09 Office
US582438A (en) * 1897-05-11 John scheidler
US231024A (en) * 1880-08-10 Machine for lining sheets of straw-board
US599865A (en) 1898-03-01 Emanuel l
US966450A (en) * 1909-06-18 1910-08-09 John W S Jones Couch or bed.
US966509A (en) * 1909-06-25 1910-08-09 Charles A Wulf Flushing-valve.
US967414A (en) * 1910-02-11 1910-08-16 William W Hallam Railway-rail.
US966939A (en) * 1910-05-02 1910-08-09 James V Mitchell Sash-lock.
US996497A (en) * 1911-03-30 1911-06-27 Kokomo Sanitary Mfg Co Tank-cover fastener.
US1036647A (en) 1911-06-19 1912-08-27 St Louis Briquette Machine Company Briquet-machine.
US1437816A (en) 1922-07-26 1922-12-05 Howard S Paine Process for preparing fondant or chocolate soft cream centers
US1505827A (en) * 1923-04-25 1924-08-19 Villasenor Eduardo Tablet-making machine
US1900012A (en) * 1925-09-04 1933-03-07 Western Cartridge Co Process of and apparatus for making wads
US2307371A (en) * 1941-08-13 1943-01-05 Ray O Vac Co Molding process
US2415997A (en) * 1946-01-12 1947-02-18 John W Eldred Article handling apparatus
US2823789A (en) * 1952-05-06 1958-02-18 Gilman Engineering & Mfg Corp Parts feeder ribbon
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
GB759081A (en) 1954-04-15 1956-10-10 John Holroyd And Company Ltd Improvements relating to machines for the production of coated tablets and the like
US2849965A (en) 1954-04-15 1958-09-02 John Holroyd & Company Ltd Machines for use in the production of coated tablets and the like
US2966431A (en) 1956-03-24 1960-12-27 Basf Ag Separation of filter material from carbon black
US2946298A (en) 1957-11-13 1960-07-26 Arthur Colton Company Compression coating tablet press
US2931276A (en) * 1958-02-10 1960-04-05 Jagenberg Werke Ag Methods of and means for producing, processing, and for treating articles
GB866681A (en) 1958-05-22 1961-04-26 May & Baker Ltd N-substituted piperidines
GB888038A (en) 1959-12-16 1962-01-24 William Warren Triggs C B E Medicinal tablet
GB936386A (en) 1959-01-16 1963-09-11 Wellcome Found Pellets for supplying biologically active substances to ruminants
US2963993A (en) 1959-01-20 1960-12-13 John Holroyd & Company Ltd Machines for making coated tablets by compression
US3096248A (en) 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3029752A (en) * 1959-07-20 1962-04-17 Stokes F J Corp Tablet making machine
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
GB990784A (en) * 1960-05-23 1965-05-05 Dunlop Rubber Co Improvements in or relating to balls
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
GB994742A (en) 1960-09-09 1965-06-10 Wellcome Found Pharmaceutical tablets containing anthelmintics, and the manufacture thereof
US3108046A (en) 1960-11-25 1963-10-22 Smith Kline French Lab Method of preparing high dosage sustained release tablet and product of this method
NL271831A (zh) * 1960-11-29
NL272604A (zh) * 1960-12-28
US3430535A (en) * 1961-08-25 1969-03-04 Independent Lock Co Key cutter
BE636865A (zh) * 1962-08-31
US3185626A (en) * 1963-03-06 1965-05-25 Sterling Drug Inc Tablet coating method
US3279995A (en) 1963-05-31 1966-10-18 Allen F Reid Shaped pellets
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3300063A (en) * 1965-01-25 1967-01-24 Mayer & Co Inc O Vacuum gripping apparatus
FR1603314A (en) * 1965-02-23 1971-04-05 Pharmaceutical tablets - having a core and a matrix material
US3328840A (en) * 1965-04-23 1967-07-04 Pentronix Inc Powder compacting press
US3279360A (en) 1965-09-13 1966-10-18 Miehle Goss Dexter Inc Machine for printing on cylindrical articles
US3330400A (en) 1966-03-08 1967-07-11 Miehle Goss Dexter Inc Mechanism for transferring cylindrical articles
GB1212535A (en) * 1966-10-12 1970-11-18 Shionogi & Co Method and apparatus for producing molded article
US3458968A (en) 1966-11-16 1969-08-05 Lester Gregory Jr Dispensing and feed mechanism
GB1144915A (en) * 1966-11-24 1969-03-12 Armour Pharma Improvements in or relating to pastille formulations
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3656518A (en) * 1967-03-27 1972-04-18 Perry Ind Inc Method and apparatus for measuring and dispensing predetermined equal amounts of powdered material
US3563170A (en) * 1968-04-16 1971-02-16 Reynolds Metals Co Machine for marking the exterior cylindrical surfaces of cans in a continous nonidexing manner
US3605479A (en) 1968-05-08 1971-09-20 Textron Inc Forming press
US3584114A (en) 1968-05-22 1971-06-08 Hoffmann La Roche Free-flowing powders
SE335202B (zh) * 1968-06-19 1971-05-17 Aco Laekemedel Ab
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
FR1581088A (zh) 1968-07-17 1969-09-12
US3567043A (en) * 1968-08-05 1971-03-02 Sun Chemical Corp Transfer assembly for use with container printing machines
US3627583A (en) * 1969-04-29 1971-12-14 Sucrest Corp Direct compression vehicles
US3604417A (en) * 1970-03-31 1971-09-14 Wayne Henry Linkenheimer Osmotic fluid reservoir for osmotically activated long-term continuous injector device
US3640654A (en) * 1970-06-25 1972-02-08 Wolverine Pentronix Die and punch assembly for compacting powder and method of assembly
US3832252A (en) * 1970-09-29 1974-08-27 T Higuchi Method of making a drug-delivery device
NL175029C (nl) 1970-12-23 1984-09-17 Boehringer Sohn Ingelheim Depotdragee, die bekleed is met een onoplosbare en onverteerbare schaal, die op een of meer plaatsen een uitsparing vertoont.
US3811552A (en) * 1971-01-11 1974-05-21 Lilly Co Eli Capsule inspection apparatus and method
US3760804A (en) * 1971-01-13 1973-09-25 Alza Corp Improved osmotic dispenser employing magnesium sulphate and magnesium chloride
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3726622A (en) * 1971-08-20 1973-04-10 Wolverine Pentronix Compacting apparatus
DE2157465C3 (de) 1971-11-19 1975-04-24 Werner & Pfleiderer, 7000 Stuttgart Füllvorrichtung für eine hydraulische Blockpresse
GB1371244A (en) * 1971-12-09 1974-10-23 Howorth Air Conditioning Ltd Machines acting on continuously running textile yarns
BE794951A (fr) * 1972-02-03 1973-05-29 Parke Davis & Co Conditionnement soluble dans l'eau
US3975888A (en) 1972-04-26 1976-08-24 R. A. Jones & Company, Inc. Method and apparatus for forming, filling and sealing packages
US3851751A (en) 1972-04-26 1974-12-03 Jones & Co Inc R A Method and apparatus for forming, filling and sealing packages
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3912441A (en) 1972-12-13 1975-10-14 Yasuo Shimada Compressing roll in rotary power compression molding machine
US3851638A (en) 1973-02-02 1974-12-03 Kam Act Enterprises Inc Force multiplying type archery bow
DE2309202A1 (de) * 1973-02-21 1974-08-29 Schering Ag Arzneiformen mit mikroverkapseltem arzneimittelwirkstoff
US3832525A (en) * 1973-03-26 1974-08-27 Raymond Lee Organization Inc Automatic heating device to prevent freezing of water supply lines
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3884143A (en) * 1973-09-04 1975-05-20 Hartnett Co R W Conveyor link for tablet printing apparatus
DE2401419A1 (de) 1974-01-12 1975-07-17 Bosch Gmbh Robert Fahrzeug mit einem hydrostatischen und mechanischen antrieb
US3891375A (en) 1974-01-21 1975-06-24 Vector Corp Tablet press
GB1497044A (en) * 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
US3988403A (en) * 1974-07-09 1976-10-26 Union Carbide Corporation Process for producing molded structural foam article having a surface that reproducibly and faithfully replicates the surface of the mold
US4139589A (en) 1975-02-26 1979-02-13 Monique Beringer Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
US4230693A (en) * 1975-04-21 1980-10-28 Armour-Dial, Inc. Antacid tablets and processes for their preparation
FR2312247A1 (fr) * 1975-05-30 1976-12-24 Parcor Derives de la thieno-pyridine, leur procede de preparation et leurs applications
US4097606A (en) * 1975-10-08 1978-06-27 Bristol-Myers Company APAP Tablet containing an alkali metal carboxymethylated starch and processes for manufacturing same
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
SE414386B (sv) 1976-03-10 1980-07-28 Aco Laekemedel Ab Sett att framstella och samtidigt forpacka farmaceutiska dosenheter
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4218433A (en) * 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4139627A (en) * 1977-10-06 1979-02-13 Beecham Inc. Anesthetic lozenges
DE2752971C2 (de) * 1977-11-28 1982-08-19 Lev Nikolaevič Moskva Koškin Spritzgießmaschine zum Herstellen von Spritzgußteilen aus thermoplastischen Werkstoffen
GB2030042A (en) * 1978-09-21 1980-04-02 Beecham Group Ltd Antacid fondant
DE2849494A1 (de) 1978-11-15 1980-05-29 Voss Gunter M Verfahren zur herstellung von arzneimittel-formlingen
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4198390A (en) 1979-01-31 1980-04-15 Rider Joseph A Simethicone antacid tablet
US4304232A (en) * 1979-03-14 1981-12-08 Alza Corporation Unit system having multiplicity of means for dispensing useful agent
US4271142A (en) * 1979-06-18 1981-06-02 Life Savers, Inc. Portable liquid antacids
US4286497A (en) * 1979-06-18 1981-09-01 Shamah Alfred A Ratchet-securable toggle retainer
JPS5827162B2 (ja) 1979-08-24 1983-06-08 株式会社ヤクルト本社 定速搬送機構
DE2936040C2 (de) * 1979-09-06 1982-05-19 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Dragierverfahren und Mittel zur Durchführung des Verfahrens, bestehend im wesentlichen aus Saccharose, wenigstens einem weiteren Zucker und Wasser
NL7906689A (nl) * 1979-09-06 1981-03-10 Dawsonville Corp Nv Tatoueerinrichting.
US4271206A (en) 1979-10-26 1981-06-02 General Foods Corporation Gasified candy having a predetermined shape
US4273793A (en) * 1979-10-26 1981-06-16 General Foods Corporation Apparatus and process for the preparation of gasified confectionaries by pressurized injection molding
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4318746A (en) * 1980-01-08 1982-03-09 Ipco Corporation Highly stable gel, its use and manufacture
US4473526A (en) 1980-01-23 1984-09-25 Eugen Buhler Method of manufacturing dry-pressed molded articles
US4292017A (en) * 1980-07-09 1981-09-29 Doepel Wallace A Apparatus for compressing tablets
US4362757A (en) 1980-10-22 1982-12-07 Amstar Corporation Crystallized, readily water dispersible sugar product containing heat sensitive, acidic or high invert sugar substances
FR2492661A1 (fr) * 1980-10-28 1982-04-30 Laruelle Claude Nouvelle forme galenique d'administration du metoclopramide, son procede de preparation et medicament comprenant cette nouvelle forme
US4683256A (en) * 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4327076A (en) * 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4340054A (en) * 1980-12-29 1982-07-20 Alza Corporation Dispenser for delivering fluids and solids
US5002970A (en) * 1981-07-31 1991-03-26 Eby Iii George A Flavor masked ionizable zinc compositions for oral absorption
IE53102B1 (en) * 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
US4372942A (en) 1981-08-13 1983-02-08 Beecham Inc. Candy base and liquid center hard candy made therefrom
DE3144678A1 (de) 1981-11-10 1983-05-19 Eugen Dipl.-Ing. 8871 Burtenbach Bühler Verfahren und einrichtung zur herstellung von formlingen aus einer rieselfaehigen masse
JPS58152813A (ja) * 1982-03-08 1983-09-10 Sumitomo Chem Co Ltd 鮮明な刻印を有する錠剤およびその製法
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
DK151608C (da) * 1982-08-13 1988-06-20 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
US4517205A (en) * 1983-01-03 1985-05-14 Nabisco Brands, Inc. Co-deposited two-component hard candy
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4882167A (en) * 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4533345A (en) * 1983-06-14 1985-08-06 Fertility & Genetics Associates Uterine catheter
FR2548675B1 (fr) * 1983-07-06 1987-01-09 Seppic Sa Compositions filmogenes pour enrobage des formes solides de produits pharmaceutiques ou alimentaires et produits obtenus revetus desdites compositions
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4781714A (en) * 1983-11-02 1988-11-01 Alza Corporation Dispenser for delivering thermo-responsive composition
AU591171B2 (en) 1983-11-02 1989-11-30 Alza Corporation Dispenser for delivering thermo-responsive composition
NL194820C (nl) 1983-11-02 2003-04-03 Alza Corp Preparaat voor de afgifte van een op warmte reagerende samenstelling.
DE3404108A1 (de) * 1984-02-07 1985-08-14 Kilian & Co GmbH, 5000 Köln Tablettenpresse
US4518335A (en) * 1984-03-14 1985-05-21 Allied Corporation Dilatant mold and dilatant molding apparatus
US4564525A (en) 1984-03-30 1986-01-14 Mitchell Cheryl R Confection products
JPS60217106A (ja) 1984-04-12 1985-10-30 高橋 信之 無機粉末凍結成形法
US4661521A (en) * 1984-04-30 1987-04-28 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4528335A (en) * 1984-05-18 1985-07-09 Phillips Petroleum Company Polymer blends
US4666212A (en) * 1984-06-15 1987-05-19 Crucible S.A. Metal value recovery
US4610884A (en) * 1984-06-29 1986-09-09 The Procter & Gamble Company Confectionery cremes
US4643894A (en) * 1984-07-24 1987-02-17 Colorcon, Inc. Maltodextrin coating
US4828841A (en) * 1984-07-24 1989-05-09 Colorcon, Inc. Maltodextrin coating
US4894234A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for antiarrhythmics
JPS61100519A (ja) * 1984-10-23 1986-05-19 Shin Etsu Chem Co Ltd 医薬用硬質カプセル
US4684534A (en) * 1985-02-19 1987-08-04 Dynagram Corporation Of America Quick-liquifying, chewable tablet
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
CA1234717A (en) * 1985-06-28 1988-04-05 Leslie F. Knebl Moist chewing gum composition
GB8517073D0 (en) 1985-07-05 1985-08-14 Hepworth Iron Co Ltd Pipe pipe couplings &c
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DK8603837A (zh) * 1985-08-13 1987-02-14
US4665116A (en) 1985-08-28 1987-05-12 Turtle Wax, Inc. Clear cleaner/polish composition
US4663147A (en) 1985-09-03 1987-05-05 International Minerals & Chemical Corp. Disc-like sustained release formulation
US5188840A (en) * 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4853249A (en) 1985-11-15 1989-08-01 Taisho Pharmaceutical Co., Ltd. Method of preparing sustained-release pharmaceutical/preparation
US5229164A (en) * 1985-12-19 1993-07-20 Capsoid Pharma Gmbh Process for producing individually dosed administration forms
DE3601516A1 (de) * 1986-01-20 1987-07-23 Agie Ag Ind Elektronik Lichtschranke
JPS62230600A (ja) 1986-03-31 1987-10-09 東洋ゴム工業株式会社 伸縮可能なフオ−クを備えたフオ−クリフト
DE3610878A1 (de) * 1986-04-01 1987-10-08 Boehringer Ingelheim Kg Formlinge aus pellets
US4873231A (en) 1986-04-08 1989-10-10 Smith Walton J Decreasing the toxicity of an ibuprofen salt
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4857330A (en) * 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
US4960416A (en) * 1986-04-30 1990-10-02 Alza Corporation Dosage form with improved delivery capability
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5200196A (en) * 1986-05-09 1993-04-06 Alza Corporation Improvement in pulsed drug therapy
US4802924A (en) 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US4757090A (en) 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4762719A (en) * 1986-08-07 1988-08-09 Mark Forester Powder filled cough product
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
DE3629994A1 (de) 1986-09-03 1988-03-17 Weissenbacher Ernst Rainer Pro Vorrichtung zur medikamentenapplikation in koerperhoehlen bzw. auf koerperoberflaechen
US4803076A (en) 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
CA1290526C (en) 1986-11-07 1991-10-15 Marianne Wieser Mold and die operation
DE3640574A1 (de) 1986-11-27 1988-06-09 Katjes Fassin Gmbh & Co Kg Verfahren zur herstellung eines essbaren pralinenfoermigen produktes und vorrichtung fuer die durchfuehrung des verfahrens
US4828845A (en) * 1986-12-16 1989-05-09 Warner-Lambert Company Xylitol coated comestible and method of preparation
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US4801461A (en) 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4820524A (en) * 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4813818A (en) 1987-08-25 1989-03-21 Michael Sanzone Apparatus and method for feeding powdered materials
US4978483A (en) 1987-09-28 1990-12-18 Redding Bruce K Apparatus and method for making microcapsules
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4851226A (en) 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4894236A (en) 1988-01-12 1990-01-16 Choong-Gook Jang Direct compression tablet binders for acetaminophen
CA1330886C (en) 1988-01-22 1994-07-26 Bend Research Inc. Osmotic system for delivery of dilute solutions
CH676470A5 (zh) * 1988-02-03 1991-01-31 Nestle Sa
US4929446A (en) * 1988-04-19 1990-05-29 American Cyanamid Company Unit dosage form
US5279660A (en) * 1988-05-24 1994-01-18 Berol Nobel Stenungsund Ab Use of viscosity-adjusting agent to counteract viscosity decrease upon temperature increase of a water-based system
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
WO1990002546A1 (en) * 1988-09-09 1990-03-22 The Ronald T. Dodge Company Pharmaceuticals microencapsulated by vapor deposited polymers and method
US5194464A (en) * 1988-09-27 1993-03-16 Takeda Chemical Industries, Ltd. Enteric film and preparatoin thereof
JPH0816051B2 (ja) * 1988-12-07 1996-02-21 エスエス製薬株式会社 徐放性坐剤
US4906478A (en) 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US4984240A (en) * 1988-12-22 1991-01-08 Codex Corporation Distributed switching architecture for communication module redundancy
US5610214A (en) * 1988-12-29 1997-03-11 Deknatel Technology Corporation, Inc. Method for increasing the rate of absorption of polycaprolactone
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5006297A (en) * 1989-02-22 1991-04-09 Acushnet Company Method of molding polyurethane covered golf balls
US4956182A (en) 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US4931286A (en) * 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US4960169A (en) * 1989-06-20 1990-10-02 Modien Manufacturing Co. Baffle for tubular heat exchanger header
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
EP0419410A3 (en) * 1989-09-19 1991-08-14 Ciba-Geigy Ag Alkanophenones
US5146730A (en) * 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
JPH03139496A (ja) * 1989-10-25 1991-06-13 Sanshin Ind Co Ltd 船舶推進機
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US5223266A (en) 1990-01-24 1993-06-29 Alza Corporation Long-term delivery device with early startup
US5100676A (en) * 1990-02-02 1992-03-31 Biosurface Technology, Inc. Cool storage of cultured epithelial sheets
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US4980169A (en) * 1990-05-03 1990-12-25 Warner-Lambert Company Flavor enhancing and increasing efficacy of cough drops
US4983394A (en) * 1990-05-03 1991-01-08 Warner-Lambert Company Flavor enhancing and medicinal taste masking agent
US5213738A (en) 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5464631A (en) * 1990-06-27 1995-11-07 Warner-Lambert Company Encapsulated dosage forms
US5133892A (en) 1990-10-17 1992-07-28 Lever Brothers Company, Division Of Conopco, Inc. Machine dishwashing detergent tablets
US5436026A (en) * 1990-11-05 1995-07-25 Mcneil-Ppc, Inc. Discharge and transfer system for apparatus for gelatin coating tablets
US5503673A (en) * 1990-11-05 1996-04-02 Mcneil-Ppc, Inc Apparatus for dip coating product
US5538125A (en) * 1990-11-05 1996-07-23 Mcneil-Ppc, Inc. Indexing and feeding systems for apparatus for gelatin coating tablets
US5228916A (en) * 1990-11-05 1993-07-20 Mcneil-Ppc, Inc. Apparatus for creating a gelatin coating
US5683719A (en) * 1990-11-22 1997-11-04 British Technology Group Limited Controlled release compositions
US5098715A (en) * 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
US5232706A (en) 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
NZ241613A (en) * 1991-02-27 1993-06-25 Janssen Pharmaceutica Nv Highlighting intagliations in tablets
CA2061520C (en) * 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190927A (en) * 1991-07-09 1993-03-02 Merck & Co., Inc. High-glyceryl, low-acetyl gellan gum for non-brittle gels
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5200191A (en) * 1991-09-11 1993-04-06 Banner Gelatin Products Corp. Softgel manufacturing process
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
DK171536B1 (da) 1991-12-06 1996-12-23 Rasmussen Kann Ind As Vindue med ramme af ekstruderede profilemner
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
GB2284760B (en) * 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
WO1993014158A1 (en) 1992-01-17 1993-07-22 Berwind Pharmaceutical Services, Inc. Film coatings and film coating compositions based on cellulosic polymers and lactose
US5427614A (en) * 1992-02-14 1995-06-27 Warner-Lambert Company Starch based formulations
US5209746A (en) * 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
GR1002332B (el) 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
EP0572731A1 (en) 1992-06-01 1993-12-08 The Procter & Gamble Company Chewable preparation containing a decongestant
US5317849A (en) 1992-08-07 1994-06-07 Sauter Manufacturing Corporation Encapsulation equipment and method
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
WO1994007470A1 (en) * 1992-09-30 1994-04-14 Pfizer Inc. Article containing a core and a coating having a non constant thickness
CA2150119C (en) * 1992-11-30 2005-03-15 Robert C. Cuca Tastemasked pharmaceutical materials
US5375963A (en) 1993-01-19 1994-12-27 Wohlwend; Clayton E. Multipurpose lifting apparatus
TW272942B (zh) * 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
US5391378A (en) * 1993-02-22 1995-02-21 Elizabeth-Hata International, Inc. Two-part medicinal tablet and method of manufacture
JP2524955B2 (ja) 1993-04-22 1996-08-14 トーワ株式会社 電子部品の樹脂封止成形方法及び装置
EP0621032B1 (en) 1993-04-23 2000-08-09 Novartis AG Controlled release drug delivery device
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US5415868A (en) 1993-06-09 1995-05-16 L. Perrigo Company Caplets with gelatin cover and process for making same
JP3054989B2 (ja) * 1993-06-19 2000-06-19 八幡 貞男 断熱発現容器
IT1264855B1 (it) 1993-06-21 1996-10-17 Zambon Spa Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
ZA944949B (en) 1993-07-12 1995-04-05 Smithkline Beecham Corp Matrix-entrapped beadlet preparation
WO1995006462A1 (en) * 1993-08-30 1995-03-09 Warner-Lambert Company Tablet coating based on a melt-spun mixture of a saccharide and apolymer
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5518551A (en) * 1993-09-10 1996-05-21 Fuisz Technologies Ltd. Spheroidal crystal sugar and method of making
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
DE4341442C2 (de) * 1993-12-04 1998-11-05 Lohmann Therapie Syst Lts Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US6060639A (en) * 1994-03-04 2000-05-09 Mentor Corporation Testicular prosthesis and method of manufacturing and filling
US5453920A (en) * 1994-03-08 1995-09-26 Eubanks; William W. Trouble light having a shroud with see-through opening
US5559110A (en) 1994-03-09 1996-09-24 The Dupont Merck Pharmaceutical Company Pharmaceutical formulations of cyclic urea type compounds
JPH07281423A (ja) * 1994-04-07 1995-10-27 Konica Corp 印刷版の製版方法
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US6020002A (en) * 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
DE69535889D1 (de) 1994-07-08 2009-01-02 Astrazeneca Ab Aus vielen Einzeleinheiten zusammengesetzte tablettierte Dosisform
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5788979A (en) * 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
IT1274034B (it) * 1994-07-26 1997-07-14 Applied Pharma Res Composizioni farmaceutiche a base di gomma da masticare e procedimento per la loro preparazione
US5849327A (en) 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
WO1996004128A1 (de) * 1994-08-03 1996-02-15 Voss Gunter M Verfahren zur herstellung von manteltabletten
DE9414065U1 (de) * 1994-08-31 1994-11-03 Roehm Gmbh Thermoplastischer Kunststoff für darmsaftlösliche Arznei-Umhüllungen
DE4431653C2 (de) 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5614578A (en) 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5738875A (en) * 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US5626896A (en) * 1994-12-09 1997-05-06 A.E. Staley Manufacturing Co. Method for making liquid-centered jelly candies
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
DE4446468A1 (de) * 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von umhüllten Tabletten
US6471994B1 (en) * 1995-01-09 2002-10-29 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
ES2124956T3 (es) * 1995-02-07 1999-02-16 Hermann Kronseder Estrella de transporte para recipientes.
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5827874A (en) 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
KR19990008430A (ko) 1995-05-09 1999-01-25 피터 존스 팔슨즈 약재를 정전코팅하기 위한 분말코팅조성물
DE59601245D1 (de) * 1995-05-13 1999-03-18 Hermann Kronseder Transportstern für Gefässe
US5627971A (en) 1995-06-01 1997-05-06 Northern Telecom Limited Machine method for determining the eligibility of links in a network
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5578336A (en) * 1995-06-07 1996-11-26 Monte; Woodrow C. Confection carrier for vitamins, enzymes, phytochemicals and ailmentary vegetable compositions and method of making
CA2223768A1 (en) 1995-06-09 1996-12-27 R.P. Scherer Corporation Suspension and soft gelatin capsules containing particulate matter
US5614207A (en) 1995-06-30 1997-03-25 Mcneil-Ppc, Inc. Dry mouth lozenge
GB9517031D0 (en) * 1995-08-19 1995-10-25 Procter & Gamble Confection compositions
EP0854718B1 (en) * 1995-09-21 2004-03-10 Pharma Pass II LLC Novel composition containing an acid-labile benzimidazole and process for its preparation
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
DE19539361A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
IT1279673B1 (it) * 1995-11-07 1997-12-16 Acma Spa Apparecchiatura e metodo per la formazione di gruppi ordinati di prodotti da alimentare a passo.
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US5807579A (en) 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
JP3220373B2 (ja) * 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US5879728A (en) * 1996-01-29 1999-03-09 Warner-Lambert Company Chewable confectionary composition and method of preparing same
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5711691A (en) * 1996-05-13 1998-01-27 Air Packaging Technologies, Inc. Self-closing and self-sealing valve device for use with inflatable structures
US5827535A (en) 1996-06-21 1998-10-27 Banner Pharmacaps, Inc. Graphically impressed softgel and method for making same
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5824338A (en) 1996-08-19 1998-10-20 L. Perrigo Company Caplet and gelatin covering therefor
US5916881A (en) * 1996-10-07 1999-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo High trehalose content syrup
US5807580A (en) 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
GB9624110D0 (en) * 1996-11-20 1997-01-08 Molins Plc Transferring rod like articles
US5830801A (en) * 1997-01-02 1998-11-03 Motorola, Inc. Resistless methods of gate formation in MOS devices
DE19710213A1 (de) * 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
US5837301A (en) 1997-04-28 1998-11-17 Husky Injection Molding Systems Ltd. Injection molding machine having a high speed turret
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
AU7375598A (en) * 1997-05-09 1998-11-27 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6149939A (en) 1997-05-09 2000-11-21 Strumor; Mathew A. Healthful dissolvable oral tablets, and mini-bars
US6433015B1 (en) * 1997-06-25 2002-08-13 Ipr-Institute For Pharmaceutical Research Ag Method for reducing body weight
TR199903280T2 (xx) * 1997-07-01 2000-11-21 Pfizer Inc. Sertralin tuzlar� ve sertralinin tutmal�-bo�altma dozaj bi�imleri.
ES2235337T3 (es) 1997-07-09 2005-07-01 Swiss Caps Rechte Und Lizenzen Ag Procedimiento y dispositivo para fabricar una forma farmaceutica multicapa, fisiologicamente tolerable.
US6103260A (en) 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US6110499A (en) * 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
US5942034A (en) * 1997-07-24 1999-08-24 Bayer Corporation Apparatus for the gelatin coating of medicaments
DE19733505A1 (de) * 1997-08-01 1999-02-04 Knoll Ag Schnell wirksames Analgeticum
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6602522B1 (en) 1997-11-14 2003-08-05 Andrx Pharmaceuticals L.L.C. Pharmaceutical formulation for acid-labile compounds
ATE216220T1 (de) * 1997-12-05 2002-05-15 Alza Corp Osmotische darreichungsform mit zwei mantelschichten
US6485748B1 (en) * 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
IL136831A0 (en) 1997-12-19 2001-06-14 Smithkline Beecham Corp Process for manufacturing bite-dispersion tablets
US6432442B1 (en) 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6110500A (en) 1998-03-25 2000-08-29 Temple University Coated tablet with long term parabolic and zero-order release kinetics
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
WO1999056934A1 (en) * 1998-05-01 1999-11-11 Fei Enterprises, Ltd. Method for injection molding manufacture of controlled release devices
US6365183B1 (en) * 1998-05-07 2002-04-02 Alza Corporation Method of fabricating a banded prolonged release active agent dosage form
CN1211078C (zh) 1998-05-15 2005-07-20 中外制药株式会社 控释制剂
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
ATE277594T1 (de) 1998-06-03 2004-10-15 Alza Corp Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
US6106267A (en) * 1998-06-05 2000-08-22 Aylward; John T. Apparatus for forming a compression-molded product
US6099865A (en) * 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6103257A (en) * 1998-07-17 2000-08-15 Num-Pop, Inc. System for delivering pharmaceuticals to the buccal mucosa
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
DE19834180A1 (de) * 1998-07-29 2000-02-03 Benckiser Nv Zusammensetzung zur Verwendung in einer Geschirrspülmaschine
US6200590B1 (en) 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
DE19840256A1 (de) 1998-09-03 2000-03-09 Basf Ag Verfahren zur Herstellung von beschichteten festen Dosierungsformen
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
JP3449253B2 (ja) * 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 硬質カプセルの製造方法
US6165512A (en) 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6183681B1 (en) * 1998-12-07 2001-02-06 Centurion International, Inc. Multi-stage insert molding method
ES2175863T3 (es) * 1999-02-10 2002-11-16 Suwelack Skin & Health Care Ag Producto liofilizado que contiene beta-1,3-glucano procedente de euglena, su preparacion y utilizacion.
US6274162B1 (en) 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
US6248361B1 (en) * 1999-02-26 2001-06-19 Integ, Ltd. Water-soluble folic acid compositions
DE19913692A1 (de) * 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6090401A (en) 1999-03-31 2000-07-18 Mcneil-Ppc, Inc. Stable foam composition
US6248760B1 (en) * 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
JP3716901B2 (ja) * 1999-04-14 2005-11-16 シオノギクオリカプス株式会社 セルロースエーテルフィルム
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
US6375963B1 (en) 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6555139B2 (en) * 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE19954420A1 (de) * 1999-11-12 2001-05-31 Lohmann Therapie Syst Lts Zubereitung, bestehend aus einer film-, folien- oder oblatenförmigen Darreichungsform mit zweischichtigem Aufbau und integrierter Kennzeichnung
DE19960494A1 (de) * 1999-12-15 2001-06-21 Knoll Ag Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
CA2395231C (en) * 1999-12-23 2006-08-15 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
DE19963569B4 (de) * 1999-12-29 2006-11-16 Reckitt Benckiser N.V. Zusammensetzung zur Verwendung in einer Geschirrspülmaschine
US6599532B2 (en) 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
FR2807034B1 (fr) 2000-03-29 2002-06-14 Roquette Freres Mannitol pulverulent et son procede de fabrication
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
GB2362350A (en) 2000-05-11 2001-11-21 Reckitt Benekiser N V Process and press for the production of tablets
US20030086972A1 (en) 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
US6727200B2 (en) * 2000-08-31 2004-04-27 Mra Laboratories, Inc. High dielectric constant very low fired X7R ceramic capacitor, and powder for making
WO2002019833A2 (en) * 2000-09-07 2002-03-14 Akpharma Inc. Edible candy compositions and methods of using the same
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
WO2002066015A1 (en) 2001-02-16 2002-08-29 Bristol-Myers Squibb Pharma Company Use of polyalkylamine polymers in controlled release devices
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
NZ530511A (en) 2001-07-16 2005-06-24 Astrazeneca Ab A tablet for treating disorders of the gastrointestinal tract comprising a proton pump inhibitor and at least one antacid that has a barrier layer to cover an enteric coating film
US6558722B2 (en) * 2001-07-18 2003-05-06 Wm. Wrigley Jr. Company Use of powdered gum in making a coating for a confection
GB0120835D0 (en) 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
US20030059466A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Delayed release tablet of venlafaxin
US6742646B2 (en) * 2001-09-28 2004-06-01 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US20030066068A1 (en) * 2001-09-28 2003-04-03 Koninklijke Philips Electronics N.V. Individual recommender database using profiles of others
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US6982094B2 (en) * 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
NZ532568A (en) 2001-09-28 2005-07-29 Mcneil Ppc Inc Modified release dosage forms
US6767200B2 (en) * 2001-09-28 2004-07-27 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US7122143B2 (en) * 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
US20040006111A1 (en) 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
ATE432065T1 (de) 2002-03-26 2009-06-15 Euro Celtique Sa Gelbeschichtete zusammensetzungen mit verzögerter freisetzung
EP1764655A3 (en) * 2002-06-11 2007-09-19 ASML Netherlands B.V. Lithographic apparatus and device manufacturing method
TW578439B (en) * 2002-10-25 2004-03-01 Ritdisplay Corp Organic light emitting diode and material applied in the organic light emitting diode
EP1633403A2 (en) * 2003-05-21 2006-03-15 Control Delivery Systems, Inc. Codrugs of diclofenac
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers

Also Published As

Publication number Publication date
DE60223269T2 (de) 2008-08-21
US20040241236A1 (en) 2004-12-02
CA2447984A1 (en) 2003-04-03
EP1429746B1 (en) 2008-08-13
NO20032363D0 (no) 2003-05-26
CN1596100A (zh) 2005-03-16
CN1592612A (zh) 2005-03-09
BR0206086A (pt) 2003-12-23
BR0206062A (pt) 2004-01-13
ATE376826T1 (de) 2007-11-15
WO2003026612A2 (en) 2003-04-03
WO2003026613A1 (en) 2003-04-03
US20040213849A1 (en) 2004-10-28
NO20032363L (no) 2003-07-23
CN100364515C (zh) 2008-01-30
MXPA04002976A (es) 2005-06-20
EP1429738B1 (en) 2007-10-31
WO2003026628A2 (en) 2003-04-03
ES2311073T3 (es) 2009-02-01
HK1072902A1 (en) 2005-09-16
CN1596102A (zh) 2005-03-16
MXPA04002980A (es) 2005-06-20
CN1638740A (zh) 2005-07-13
NO20032364D0 (no) 2003-05-26
CA2446759A1 (en) 2003-04-03
US7635490B2 (en) 2009-12-22
ATE404179T1 (de) 2008-08-15
WO2003026629A3 (en) 2004-03-04
US20030219484A1 (en) 2003-11-27
US20090155372A1 (en) 2009-06-18
JP2005529059A (ja) 2005-09-29
US20040170750A1 (en) 2004-09-02
WO2003026628A3 (en) 2003-05-01
NO20032362L (no) 2003-07-14
EP1463489A1 (en) 2004-10-06
JP2005535558A (ja) 2005-11-24
US8545887B2 (en) 2013-10-01
JP2005508325A (ja) 2005-03-31
KR20040045030A (ko) 2004-05-31
BR0212921A (pt) 2004-10-13
US7416738B2 (en) 2008-08-26
CA2461616A1 (en) 2003-04-03
DE60239945D1 (de) 2011-06-16
CN1592613A (zh) 2005-03-09
KR20040037206A (ko) 2004-05-04
JP2005511515A (ja) 2005-04-28
WO2003026627A1 (en) 2003-04-03
PL369134A1 (en) 2005-04-18
KR20040037203A (ko) 2004-05-04
BR0212946A (pt) 2004-10-26
EP1429724B1 (en) 2013-11-06
MXPA04002973A (es) 2005-06-20
MXPA04002992A (es) 2005-06-20
WO2003026625A1 (en) 2003-04-03
CN1592611A (zh) 2005-03-09
US7972624B2 (en) 2011-07-05
US20040241208A1 (en) 2004-12-02
JP2005508328A (ja) 2005-03-31
KR20040045032A (ko) 2004-05-31
US20030235616A1 (en) 2003-12-25
NZ532568A (en) 2005-07-29
WO2003026624A9 (en) 2004-05-06
US20030232083A1 (en) 2003-12-18
EP1438018A1 (en) 2004-07-21
BR0212951A (pt) 2004-10-26
US20040018327A1 (en) 2004-01-29
NO20041613L (no) 2004-04-20
EP1438018B1 (en) 2010-08-11
ES2295427T3 (es) 2008-04-16
KR20040045026A (ko) 2004-05-31
CN1596101A (zh) 2005-03-16
EP1438030A2 (en) 2004-07-21
WO2003026615A3 (en) 2003-07-31
DE60237294D1 (de) 2010-09-23
KR20040045033A (ko) 2004-05-31
ATE476957T1 (de) 2010-08-15
WO2003026616A1 (en) 2003-04-03
WO2003026629A2 (en) 2003-04-03
KR20040045034A (ko) 2004-05-31
WO2003026626A2 (en) 2003-04-03
CN100408029C (zh) 2008-08-06
JP2005508326A (ja) 2005-03-31
CO5570655A2 (es) 2005-10-31
DE60223269D1 (de) 2007-12-13
BR0213589A (pt) 2004-08-31
BR0212950A (pt) 2004-10-26
KR20040066094A (ko) 2004-07-23
EP1429738A2 (en) 2004-06-23
CA2461870A1 (en) 2003-04-03
HUP0401686A2 (hu) 2004-11-29
US20080305150A1 (en) 2008-12-11
CN1592610A (zh) 2005-03-09
CA2461659A1 (en) 2003-04-03
BR0213593A (pt) 2004-08-31
US20050266084A1 (en) 2005-12-01
US7968120B2 (en) 2011-06-28
US20050019407A1 (en) 2005-01-27
CA2461659C (en) 2010-12-07
BR0206061A (pt) 2004-01-13
MXPA04002975A (es) 2005-06-20
US20030232082A1 (en) 2003-12-18
CA2446760A1 (en) 2003-04-03
WO2003026625A9 (en) 2004-05-06
MXPA04002884A (es) 2005-06-20
WO2003026614A1 (en) 2003-04-03
WO2003026626A3 (en) 2003-10-16
US20040213848A1 (en) 2004-10-28
CA2461682A1 (en) 2003-04-03
EP1432404A1 (en) 2004-06-30
WO2003026614A9 (en) 2004-02-26
WO2003026612A3 (en) 2003-06-26
EP1429724A1 (en) 2004-06-23
EP1429742B1 (en) 2011-05-04
PT1429738E (pt) 2007-12-14
CA2461354A1 (en) 2003-04-03
EP1429746A2 (en) 2004-06-23
ATE507823T1 (de) 2011-05-15
JP2005508329A (ja) 2005-03-31
WO2003026624A1 (en) 2003-04-03
EP1438028A1 (en) 2004-07-21
NZ532096A (en) 2006-10-27
KR20040045031A (ko) 2004-05-31
MXPA04002981A (es) 2005-06-20
MXPA04002974A (es) 2005-06-20
CA2461653A1 (en) 2003-04-03
EP1429742A2 (en) 2004-06-23
WO2003026630A1 (en) 2003-04-03
NZ532097A (en) 2006-02-24
JP2005509605A (ja) 2005-04-14
AU2002330164A1 (en) 2003-04-07
CA2461684A1 (en) 2003-04-03
JP2005508327A (ja) 2005-03-31
KR20040037208A (ko) 2004-05-04
EP1429737A1 (en) 2004-06-23
CA2461656A1 (en) 2003-04-03
BR0213591A (pt) 2004-08-31
CA2461354C (en) 2010-04-27
BR0213588A (pt) 2004-08-31
WO2003026615A2 (en) 2003-04-03
MXPA04002891A (es) 2005-06-20
JP2005508330A (ja) 2005-03-31
HUP0401686A3 (en) 2008-04-28
MXPA04002978A (es) 2005-06-20
NO20032364L (no) 2003-07-25
EP1429745A2 (en) 2004-06-23
KR20040037207A (ko) 2004-05-04
MXPA04002977A (es) 2005-06-20
DE60228281D1 (de) 2008-09-25
US20040062804A1 (en) 2004-04-01
MXPA04002979A (es) 2005-06-20
EP1429743A1 (en) 2004-06-23
JP2005509604A (ja) 2005-04-14
ES2444549T3 (es) 2014-02-25
NO20032362D0 (no) 2003-05-26
CN1596104A (zh) 2005-03-16
CA2461865A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
CN1607945A (zh) 有镶嵌部分的组合剂型
CN1946378A (zh) 组合剂型
US7807197B2 (en) Composite dosage forms having an inlaid portion
JP2008518027A (ja) マイクロレリーフ表面を備えた剤形およびこのような剤形を製造するための方法および装置
JP2009530420A (ja) 無作為な被覆を有する剤形
CN101048143A (zh) 具有微起伏表面的剂型及其制造方法和装置
CN1700908A (zh) 具有两个核的改进释放剂型
WO2006047689A2 (en) Dosage forms having a microreliefed surface and methods and apparatus for their production
MX2008012575A (es) Revestimientos no homogeneos de formas de dosificacion.
CN101048146A (zh) 具有微浮雕表面的剂型及其制造方法和装置
CN101048147A (zh) 具有微起伏表面的剂型及其制造方法和装置
CA2587104A1 (en) Dosage forms having a microreliefed surface and methods and apparatus for their production
CN101048145A (zh) 具有微浮雕表面的剂型及其制造方法和装置
CN101048144A (zh) 具有微起伏表面的剂型及其制造方法和装置
CN101048142A (zh) 具有微起伏表面的剂型及其制造方法和装置
CN101048148A (zh) 具有微浮雕表面的剂型及其制造方法和装置
AU2002337783A1 (en) Dosage forms having an inner core and outer shell with different shapes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080806

Termination date: 20170928